

**ELIZABETH MARY SWISHER, M.D.**

**BIRTHPLACE** Dublin, Ireland

**CITIZENSHIP** United States of America

**BUSINESS ADDRESS** Department of Obstetrics & Gynecology, Box 356460  
University of Washington School of Medicine  
Seattle, Washington 98195-6460

**BUSINESS PHONE** (206) 543-3669

**E-MAIL** swishere@uw.edu

**EDUCATION AND TRAINING**

**UNDERGRADUATE**

1983-1987 Yale University BS, 1987  
New Haven, Connecticut

**GRADUATE**

1988-1992 University of California San Diego School of Medicine MD, 1992  
La Jolla, California

**POSTGRADUATE**

INTERNSHIP 1992-1993 University of Washington School of Medicine  
Department Obstetrics and Gynecology  
Seattle, Washington

RESIDENCY 1993-1996 University of Washington School of Medicine  
Department Obstetrics and Gynecology  
Seattle, Washington

FELLOWSHIP 1996-1999 Washington University  
Division of Gynecologic Oncology, Dept. Obstetrics and Gynecology  
St. Louis, Missouri

LEADERSHIP 2025 University of Washington Foster School of Business Executive Education:  
Leadership that shapes the future.

**APPOINTMENTS AND POSITIONS**

**ACADEMIC**

1986-1987 Department of Obstetrics and Gynecology Research  
Reproductive Immunology Assistant  
Yale University, New Haven, Connecticut

1988 Division of Endocrinology, Genentech Inc. Research Intern  
South San Francisco, California

1988-1990 Department of Hematology and Oncology Research  
University of California San Diego Cancer Center Assistant  
San Diego, California

1996-1999 Department of Obstetrics and Gynecology Gyn Oncology  
Washington University School of Medicine Instructor

St. Louis, Missouri

1999-2002	Women's Reproductive Health Research Career Development Grant University of Washington School of Medicine Seattle, Washington	Research Scholar
1999-2001	Department of Obstetrics and Gynecology University of Washington School of Medicine Seattle, Washington	Acting Asst. Professor
2001-2007	Department of Obstetrics and Gynecology University of Washington School of Medicine Seattle, Washington	Assistant Professor
2001-present	Division of Public Health Sciences Fred Hutchinson Cancer Research Center Seattle, Washington	Affiliate Investigator
2002-2018	Breast and Ovarian Cancer Prevention Program Seattle Cancer Care Alliance, Seattle, Washington	Medical Director
2003-2007	Department of Medicine, Division of Medical Genetics University of Washington School of Medicine Seattle, Washington	Adjunct Assistant Professor
2005-present	Gynecologic Oncology Fellowship, University of Washington School of Medicine Seattle, Washington	Director of Research
2007-2012	Department of Obstetrics and Gynecology University of Washington School of Medicine Seattle, Washington	Associate Professor
2007-2012	Department of Medicine, Division of Medical Genetics University of Washington School of Medicine Seattle, Washington	Adjunct Associate Professor
2012-present	Department of Obstetrics and Gynecology University of Washington School of Medicine Seattle, Washington	Professor
2012-present	Department of Medicine, Division of Medical Genetics University of Washington School of Medicine Seattle, Washington	Adjunct Professor
2014-present	UW Medicine Valley Medical Center, Department of Obstetrics and Gynecology Renton, Washington	Courtesy Medical Staff
2017-2020	Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Seattle, WA	Director

2017-present	Breast and Ovarian Cancer Research Program Fred Hutchinson/UW/Seattle Children's Cancer Consortium Seattle, Washington	Co-Leader
2018-present	Brotman Baty Institute for Precision Medicine University of Washington School of Medicine Seattle, Washington	Member
2020-present	Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Seattle, WA	Director of Research
2022-present	Fred Hutchinson /University of Washington/ /Seattle Children's Cancer Consortium Seattle, Washington	Co-Deputy Director
January 2022-July 2022	Women's Reproductive Health Research (WRHR) University of Washington School of Medicine Seattle, Washington	Associate Research Director
July 2022-present	Women's Reproductive Health Research (WRHR) University of Washington School of Medicine Seattle, Washington	Research Director
January 2025-present	Gynecologic Oncology Fred Hutchinson Cancer Center Seattle, Washington	Clinical Director

### **HONORS**

1987	Cum laude, Yale University
1992	University of California San Diego Award for Excellence in Obstetrics and Gynecology
1995	J.G. Moore Award, Western Association of Gynecologic Oncologists
1996	Chief Resident Teaching Award, University of Washington
1997	J.G. Moore Award, Western Association of Gynecologic Oncologists
1997	SmithKline Beecham Educational Award
2002	Kimmel Scholar Award, Sidney Kimmel Foundation for Cancer Research
2003	CREOG National Faculty Teaching Award
2010	Margaret Greenfield/Carmel Cohen, MD Excellence in Ovarian Cancer Research Prize, Gynecologic Cancer Foundation
2011, 2012	Seattle Magazine Top Doctors Award
2012	Genome Advance of the Month, National Human Genome Research Institute, January 2012
2013	Rosalind Franklin Award for Ovarian Cancer Research, Ovarian Cancer National Alliance
2016-2025	Seattle Met Magazine Top Doctors Award
2017	Resident Research Mentoring Award, University of Washington Department of Obstetrics and Gynecology
2019	UW Medicine Award for Excellence in Mentoring Women Faculty
2021	Society of Gynecologic Oncology Innovation Award
2022	Elected, American Association of Physicians
2022	Te Linde Endowed Lecture, Johns Hopkins, Baltimore, MD
2025	Torkelson Family Endowed Chair
2026	Director's Visiting Professor, February 26-27, Sidney Kimmel Cancer Center, Baltimore, MD

## **BOARD CERTIFICATION**

2001-present American Board of Obstetrics and Gynecology

2003-present Division of Gynecologic Oncology, American Board of Obstetrics and Gynecology

## **MEDICAL LICENSURE**

1992-present Physician and Surgeon, State of Washington (MD 00032247)

1993 Diplomate, National Board of Medical Examiners

2020 Physician Temporary License, States of Oregon, Alaska, Montana, Idaho, Wyoming

## **DIVERSITY, EQUITY, AND INCLUSION ACTIVITIES**

1. **Recruitment and Mentorship** of under-represented in medicine (URM) and other diverse trainees and faculty.
  - a. We made an intentional decision many years ago to recruit URM candidates to our gynecologic fellowship and support those trainees in their oncology and academic careers. We have continued to investigate best practices to reduce implicit bias in the application and interview process and have updated our screening and interview processes accordingly. These efforts have been very successful at diversifying our candidate pool and trainees.
  - b. Support of female and non-binary faculty. While women are not under-represented in medicine, they are under-represented in leadership roles and as clinician scientists. I have a long list of female early career faculty that I have mentored, including two from outside institutions who have recently received tenure (our institution does not have a tenure track for medical faculty). For example, one of my previous trainees and subsequent faculty mentee recently became our Departmental Vice-Chair of Research, a position to which I had encouraged her to apply. As research director for our WRHR K12 career development program for early faculty in Ob/Gyn, I closely monitor and support our scholars, meeting with them monthly for research and career feedback, providing them leadership opportunities when able. In recognition of these efforts, I received the prestigious 2019 UW Medicine Award for Excellence in Mentoring Women Faculty.
  - c. I am the mentor for Bill Howard PhD, Associate Professor, Department of Chemistry & Biochemistry, University of Alaska Fairbanks for his application for an NIH R16 award. The SuRE-First awards provide support for investigator-initiated research at resource-limited institutions by full-time faculty who have not had any prior independent, peer-reviewed, external research grants and supports research capacity building.
  
2. **Research in the field of health equity:**
  - a. Promoting health equity in access to genetic testing for cancer susceptibility: I have published a large body of work to better understand genetic risk distribution in individuals with ovarian cancer and promote universal testing for ovarian cancer patients (Walsh et al, PNAS 2011, Norquist et al, Jama Oncol, 2019). I recruited Black women with ovarian cancer to a genetic study (supported by DoD funding) and published on their rate of inherited ovarian cancer susceptibility mutations in order to overcome the misconception that genetic risk is less common in Black individuals with ovarian cancer (Somasegar et al, Gynecol Oncol, 2021). As a 10-year member of the NCCN panel for Genetic/Familial High-Risk Assessment: Breast and Ovarian Panel, I worked with other panel members to translate these genetic advances into clinical practice guidelines and influenced practice statements from SGO and ACOG that recommend providing comprehensive genetic testing of multiple genes to all women with ovarian cancer, regardless of race/ethnicity, age at diagnosis, histology, or family history.
  - b. Implementation of genetic risk assessment in underserved populations. I was PI of the EDGE study (U01 CA232795, NCT04746794), which was a randomized intervention to improve genetic risk identification in primary care clinics. We intentionally chose two healthcare systems that are neither academic nor highly resourced in order to try to improve genetic risk assessment in real-world settings of greatest need. Multicare serves an urban, diverse patient population, while the Billings

Clinic serves a predominantly rural patient base in Montana, Idaho and Wyoming. Numerous papers from that trial have been published including the main outcomes (PMID: 40053353)

- c. I am on the scientific advisory board of the SISTER study (Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence, NCT04930159), a randomized intervention to improve outcomes for Black individuals with endometrial cancer that are undergoing systemic therapy (PI Kemi Doll, funded by PCORI).
- d. I am PI of a pilot study to implement cervical cancer screening using HPV self-collection into an under screened population in an American Indian Health Clinic serving individuals with opioid use disorder. This clinic not have access to gynecologic services, so utilizing HPV self-collection in this setting is bringing screening to an at-risk population that is currently under-screened. We have had both high uptake and high rates of positive HPV screens and are working to improve and simplify work flow to allow dissemination to other community opioid treatment programs.

### **MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES**

American Association of Cancer Research  
American College of Obstetricians and Gynecologists  
American Society of Clinical Oncology  
Gynecologic Oncology Group  
NRG Oncology  
Society of Gynecologic Oncology  
Southwest Oncology Consortium  
Western Association of Gynecologic Oncologists

### **NATIONAL COMMITTEES AND SERVICE**

#### **Past**

2002-2004	Education Committee, Society of Gynecologic Oncology
2003-2006	Awards Committee, Gynecologic Cancer Foundation
2004, 2005	Review Committee, Marsha Rivkin Center for Ovarian Cancer Research
2004-2010	Breast Cancer Information Core (BIC) Advisory Board
2005-2010	Women's Bioethics Project, Scientific Advisory Board
2005-2008	Cancer Genetics Education Committee, American Society of Clinical Oncology
2007-2008	Cancer Genetics Education Track Leader, American Society of Clinical Oncology
2008-2009	Program Committee, Society of Gynecologic Oncologists
2008-2009	Scientific Review Panel, Developmental Research Program, POCRC
2009-2017	National Comprehensive Cancer Network, Genetic/Familial High-Risk Assessment: Breast and Ovarian Panel
2011-2014	Committee of Experimental Medicine, Gynecologic Oncology Group (GOG)
2013-2015	Education Committee, Society of Gynecologic Oncology
2013-2016	Scientific Advisory Committee, Ovarian Cancer Research Fund
2013-2014	2014 Western Association of Gynecologic Oncology Annual Meeting Program Committee
2013-2016	Genetics and Cancer Outreach Workgroup, Society of Gynecologic Oncology
2014-2018	Scientific Advisory Board, Fanconi Anemia Research Fund
2014-2021	Chair, Translational Science Steering Committee, GOG-3005 clinical trial
2015-2018	Council, Society of Gynecologic Oncology, elected
2015-2018	Board, Foundation for Gynecologic Oncology, elected
2015-2018	Clinical Practice Committee, Society of Gynecologic Oncology
2015-2016	Ad hoc member, National Cancer Institute P01 Application Review Committee
2015	Team Science Award Selection Committee, American Association for Cancer Research
2015	Stand Up To Cancer Innovative Research Grants Committee (IRGC)
2016-2018	Publications Committee Board Liaison, Society of Gynecologic Oncology
2016-2017	Member, 2017 AACR Annual Meeting Program Committee
2016-2018	Member, MD Anderson Cancer Center NIH T32 Grant "Training of Gynecologic Oncologists" External Advisory Panel

2016-2018 Investigator, BRCA-Related Cancer: Risk Assessment, Genetic Counseling and Genetic Testing, US Preventive Services Task Force

2017-2018 Member, American Association for Cancer Research (AACR) Annual Meeting Clinical Trials Program Committee

2017 Session Chair CTSY01: Cyclin-dependent Kinase and PARP Inhibitor Clinical Trial, Clinical Trials Plenary Session at the AACR Annual Meeting April 3, 2017

2018 Small Group Leader: SGO Curriculum for Emerging Clinical Trialists, Breakout Session on Career Mentoring, SGO Annual Meeting New Orleans, LA March 23, 2018.

2018-2025 Translational Co-Chair, NRG Oncology Ovarian Cancer Committee

2019 Member, 2019 SGO Nominating Committee

2019 Member, Center for Scientific Review Special Emphasis Panel, PAR-16-089: Imaging and Biomarkers for Early Cancer Detection (U01)

2019 Member, AACR Burchenal Translational Science Award Selection Committee

2019 Reviewer, NIH Director's Early Independence Awards (DPS)

2019-2024 Member, Society of Gynecologic Oncology Research Taskforce

2020 Chair, AACR Clinical Cancer Research Awards Committee

2020 Ad hoc Reviewer, NIH Clinical Oncology (CONC) Study Section

2021 Co-Chair, AACR Special Conference, Ovarian Cancer, (virtual), Sept 14-15, 2021,

2020-2021 Member, NCI Ovarian Cancer Clinical Trials Planning Taskforce

2021-2022 Member, AACR Annual Meeting DNA Damage and Repair Program Sub-committee

2022 Participant, Forbeck Forum: Challenges and Opportunities for Transformative Therapeutic Development for Ovarian Cancer

2022 Session chair, ASCO National Meeting Education Track: Addressing Challenges in Ovarian Cancer Management

2020, 2022 Member, NIH ZRG1 OBT-D (55) Cancer Research Workforce Diversity Review Meeting

2022 Member, NIH 10 ZCA1 TCRB-J (O1) S Special Emphasis Panel on Clinical and Translational Cancer Research

2022-2023 Member, Data Safety Monitoring Board, Novartis

2022-2023 Co-Chair, AACR Special Conference, Ovarian Cancer, Boston, MA, Oct 5-7, 2023

2023-2024 Co-chair, AACR 2024 Annual Meeting Program Committee

2024-2025 Co-chair, 2025 AACR Special Conference on Ovarian Cancer, Denver, CO, Sep 19-21, 2025

2025 Ad Hoc Reviewer, NIH Molecular Cancer Diagnosis and Classification Study Section

### **Current**

2011-present Member, Scientific Advisory Board, Facing our Risk of Cancer Empowered (FORCE)

2014-present Member, Steering Committee, GOG-3005 clinical trial

2014-present Member, Translational Science Committee, NRG Oncology

2015-present Member, Scientific Advisory Board, IDEAYA Biosciences

2016-present Chair, Mayo Clinic Ovarian SPORE External Advisory Board

2018-present Member, Dana-Farber Cancer Institute Ovarian SPORE External Advisory Board

2018-present Chair, MD Anderson Cancer Center Gynecologic Oncology T32 Training Program External Advisory Board

2019-present Chair, Any Mountain Expedition Team (non-profit)

2021-present Member, External Advisory Board, SISTER Study

2025-present Member, AACR Science Policy and Government Affairs Committee

2025-2026 Elected Chair-elect, AACR Cancer Prevention Work Group

2025-2026 Chair, Clinical Prevention, Early Detection, and Interception Section of the 2026 AACR Annual Meeting Program Committee

2025-current Member, Data Safety Monitoring Board, AstraZeneca TREVI trial

2026 Member, AACR-Women in Cancer Research Charlotte Friend Lectureship Committee

### **LOCAL COMMITTEES AND SERVICE**

2003 Grant Reviewer, The Marsha Rivkin Foundation for Ovarian Cancer Research

2005 Reviewer, The Marsha Rivkin Foundation for Ovarian Cancer Research  
 2005-present Member, Advisory Board, Women's Reproductive Health Research K12 Training Program, University of Washington  
 2006, 2007 Reviewer, University of Washington Royalty Research Foundation  
 2015-2021 Steering Committee, Cancer Consortium T32 Interdisciplinary Training Grant  
 2016-2017 Search Committee, University of Washington Ob/Gyn Chair  
 2017 Reviewer, Institute of Translational Health Sciences (ITHS) 2017 Pilot Award Program  
 2017 Reviewer, Seattle Translational Tumor Research (STTR) Grant Program  
 2017 Selection Committee, Nancy Kelley Jensen Endowed Faculty Fellowship in Gynecologic Oncology Research  
 2018 Ovary Deputy Director, Seattle Translational Tumor Research (STTR)  
 2018 Co-Chair, Planning Committee 2018 Biennial Rivkin Ovarian Cancer Research Symposium  
 2019 -present Internal Advisory Board, Pacific Northwest Prostate Cancer SPORE  
 2019-present Member, Executive Committee Medical and Gynecologic Oncology UW/Fred Hutch T32 Medical Oncology/Gynecologic Oncology Training Program  
 2024-2025 Member, Search Committee UW Gynecologic Oncology Division Director  
 2024-2025 Chair, Search Committee, Fred Hutch Cancer Center, Director of Cancer Genetics  
 2025 Member, Search Committee, Fred Hutch Cancer Center, Director of Surgical Oncology

## **TEACHING RESPONSIBILITIES**

### **MENTORSHIP**

#### **PRE-DOCTORAL**

Sarita Mahtani: Undergraduate research and clinical mentorship. Basic science research project including Mary Gates Research Fellowship, November, 2000-May, 2002 evaluating free tumor DNA in body fluids of women with ovarian cancer (co-author PMID: 16579938) Subsequently matriculated and graduated from the University of Washington School of Medicine. Currently an Assistant Professor of Clinical Medicine at Cornell University and Weill Cornell Medicine.

Melissa Wollan Francis: Post- baccalaureate laboratory research training and clinical mentorship, May 2002-May, 2004. Co-authored three papers (PMID: 17171684, PMID: 17023036, PMID: 16150257). Subsequently graduated Yale University School of Medicine, currently Obstetrics and Gynecology physician in Portland, OR.

Kaitlyn Wurz (now Wald): Undergraduate Syracuse University, Summer internship, laboratory and clinical mentorship, May-August 2005 and May-August, 2006. Post- baccalaureate fellowship 2007-2009. She co-authored 6 papers and was 1<sup>st</sup> author for two papers. Graduated University of Washington SOM, completed Ob/Gyn residency University of Washington and fellowship in Reproductive Endocrinology and Infertility (REI) at UC San Francisco. Currently REI specialist in Seattle, WA.

Kyrsten Stoops, medical student. Mentored during ASCO summer research fellowship and supervised student thesis: A Self-administered Family History Questionnaire Improves Identification of Women that should be Referred to Genetic Counseling. One publication. Currently family practice physician. April 2008-June 2010.

Sarah Bernards, pre-medical student and medical student, supervised multiple research projects related to the genetics of ovarian cancer including 1. Inherited susceptibility of ovarian cancer in women diagnosed at 40 or younger. 2. The role of promoter methylation of BRCA1 and RAD51C and outcomes in ovarian cancer. She published two first-author papers. Currently, she is the Chief Gastroenterology Fellow at UW.

Emily Kohlbrenner, Ph.D. graduate student University of Washington Department of Pathology, Molecular Medicine and Mechanism of Disease Program, member thesis committee 2018-present

Elizabeth Oestreich, MPH student, University of Washington Institute for Public Health Genetics, Breast and Ovarian Cancer Prevention Program Study, co-mentor, 2018-2019

Ariel Garcia, University of Washington School of Medicine Second Year Student, summer wet lab internship 2022.

Tesla Theoryn, PhD Candidate, University of Washinton, Institute of Public Health Genetics. Member, Dissertation Committee 2024 and co-mentor on multiple studies related to mixed-methods analyses of genetic testing uptake.

#### **POST DOCTORAL**

Julia Willner, MD Post-doctoral laboratory experience, April 2004-June, 2005. First author one paper (PMID: 17258789) and co-author 3 papers. Completed residency in Obstetrics and Gynecology at University of California at Irvine.

Vijaya Galic, MD Post-doctoral laboratory experience, April 2005-June, 2006. First author one paper (PMID: 17171684) and co-author 2 papers. She completed residency in Obstetrics and Gynecology, and fellowship gynecologic oncology at Columbia University, NY. Currently a gynecologic oncologist in El Paso, Tx.

Julie Lamb, MD, resident Department of Obstetrics and Gynecology. Mentored Husky Day project and research project: Predictors of Occult Neoplasia in Women Undergoing Risk-Reducing Salpingo-oophorectomy. Resulted in resident research award at the Pacific Coast Gynecologic Society, 2005 and first author publication (PMID: 16731090). November, 2004- March, 2006. Currently REI specialist in Seattle, WA and Clinical Associate Professor at the University of Washington.

Christiana Dello Russo, PHD: post-doctoral fellow, Supervised project: Angiogenesis Angiogenic Alterations and Circulating Tumor DNA in Women with Ovarian Cancer, March 2005-March, 2006.

Chirag Shah MD, resident, Department of Obstetrics and Gynecology. Supervised resident research project: inflammatory cells and Circulating Tumor DNA in Women with Ovarian Cancer. October, 2005-present. Subsequently completed fellowship in gynecologic oncology at the University of Washington.

Ruchi Garg MD, fellow Division of Gynecologic Oncology, Supervised research project and helped write manuscript accepted for publication on project: IL6 polymorphisms and ovarian and peritoneal cancer outcomes. September, 2005-August, 2006.

Barbara Norquist, MD, resident, fellow and faculty, Department of Obstetrics and Gynecology. Supervised resident research project: Tubal origin of primary peritoneal and ovarian carcinomas. Supervised two year post-doctoral fellow laboratory research. May, 2006-June, 2010.

Joshua Press MD, gynecologic oncology fellow. Supervised two year post-doctoral fellow laboratory research. Molecular genetics of ovarian cancer. July 2007-June 2009. Currently on faculty at McGill University in Department of Obstetrics and Gynecology.

Kara Hoppe MD, obstetrics and gynecology resident. Supervised research project: expression of tumor markers in adult and fetal ovarian and fallopian tubes. June 2009-2010. She is a Maternal-Fetal Medicine specialist and Associate Professor at University of Wisconsin with a focus on advancing care and health equity for pregnant persons and research focused specifically on hypertension during pregnancy and postpartum.

Na Lu Smith MD, PhD: Post-doctoral fellowship, then entered medical school University of South Dakota and currently a resident in Radiation Oncology at the Mayo Clinic. Evaluated E2F3b over-expression in ovarian carcinomas and in BRCA1 haplo-insufficient fallopian tube epithelium. July, 2010-July, 2012

Mary Jenkins Vogel MD, obstetrics and gynecology resident. Supervised two research projects: angiogenesis in ovarian cancers and development of a questionnaire to assess familial cancer risk, resulting in 2 first author

papers. February 2010-December 2012. She is a Clinical Assistant Professor at NorthShore and the University of Chicago, Division of Gynecologic Oncology.

Kathryn Pennington MD, gynecologic oncology fellow. Supervised two year post-doctoral fellow laboratory research. Used massively parallel sequencing to study germline and somatic alterations in DNA repair genes in ovarian cancer. 4 first author publications, 2 co-author publications. July 2011- July 2013. She is currently Director of Clinical Trials, Alaska Women's Cancer Care, Anchorage, AK and National PI of NRG Oncology's SOROCK ovarian cancer prevention trial.

Christopher Morse MD, obstetrics and gynecology resident, supervised residency research project investigating the fraction of tumor nuclei in banked ovarian cancers as a predictor of tumor biology and patient outcomes. 2013-2016, Supervised fellowship research project on immunophenotype of ovarian cancers with and without homologous recombination deficiency. First author publication. 2017--2020. Currently, attending gynecologic oncologist, Pittsburgh, PA.

Carrie McIlwain MD, MPH, obstetrics and gynecology resident, supervised residency research project on the risk of primary peritoneal cancer following risk reducing surgery for an inherited mutation in BRCA1 and BRCA2. Currently, attending gynecologic oncologist, Oak Lawn, IL. 2013-2016.

Lauren Stewart MD, obstetrics and gynecology resident, supervised residency research project on patient attitudes after salpingectomy for ovarian cancer risk reduction. Currently, Assistant Professor, Department of Ob/Gyn, NYU Grossman School of Medicine. 2014-2016.

Kaitlyn Wald MD, obstetrics and gynecology resident, supervised residency research project on the relationship of BRCA1 mutation type and clinical response to platinum and PARP inhibitors in ovarian cancer. First author publication. Currently, reproductive endocrinology specialist, Seattle, WA. 2014-2017.

Shannon Rush MD, obstetrics and gynecology resident, supervised residency research project on predictive factors for choosing prophylactic bilateral mastectomy amongst women with BRCA1 and BRCA2 mutations. First author publication. 2018. Currently Assistant Professor, Gynecologic Oncology, University of Pittsburgh

Talayeh Ghezelayagh MD, MPH, obstetrics and gynecology resident and gynecologic oncology fellow, supervised multiple research projects related to molecular genetics of ovarian cancer. Co-mentor on T32 fellowship. 2 first author and 1 co-author publications. 2016-2022. Currently an Acting Instructor at Stanford University.

Sushmita Gordhandas MD, resident, Cornell Weill Department of Obstetrics and Gynecology, Comprehensive review of risks and benefits of hormone replacement therapy in BRCA mutation carriers following surgical menopause. 1<sup>st</sup> Author publication, currently gynecologic oncology fellow, Memorial Sloan Kettering, 2018-2019.

Soledad Jorge MD, MPH, gynecologic oncology fellow, University of Washington. Supervised projects related to BRCA mutation and clinical course and the role of simultaneous germline/somatic genetic testing in women with ovarian cancer, 2018-2019, currently Acting Assistant Professor, Department of Ob/Gyn, University of Washington.

Isabel Rodriguez MD, gynecologic oncology fellow, T32 mentor. Development of a combined mutation and methylation assay to predict excellent response to PARP inhibition. 2020-2024

Ann Oluloru MD, gynecologic oncology fellow, T32 co-mentor, Unblinding the disparities within: a critical evaluation of gynecologic cancer clinical trials using a health equity lens, 2021-present

Darien Reed MD, PhD, medical oncology fellow, T32 co-mentor. Identifying novel synthetic lethal genetic combinations with PARP inhibitors in unselected triple-negative breast tumors. 2021-2023

Eric Rios-Doria, MD, MPH, gynecologic oncology fellow, T32 co-mentor, Somatic load of TP53 mutations in the endometrium of Black and White Individuals. 2022-2024

Tiffany Jones, MD, MS, gynecologic oncology fellow, T32 primary basic science mentor, Multiomic profiling of high and low risk endometrial cancer, 2024-present

### **Early Faculty**

Barbara Norquist MD, Associate Professor and current Vice-chair of Research, Dept Ob/Gyn, University of Washington. I was Dr. Norquist's mentor on K-12 Women's Reproductive Health Research fellowship 2012-2014, mentor on Marsha Rivkin Center for Ovarian Cancer Research Scientific Scholar Award, and mentor on Liz Tilberis Career Development Award 2014-2016.

Kristen Zorn M.D., Associate Professor and Director, Division of Gynecologic Oncology, University of Arkansas, Tenure Track Committee Member, 2015-2021.

Jung-Min Lee M.D., Investigator and Lasker Clinical Research Scholar, Women's Malignancies Branch Center for Cancer Research, National Cancer Institute, Tenure Track Committee Member, 2017-2023. Received Tenure 2023.

Bo Yu MD, Assistant Professor Department of Obstetrics and Gynecology, K08 mentor, The role of fallopian tube microbiome in ovarian carcinogenesis, Currently, Assistant Professor, Department of Ob/Gyn, Stanford University. 2017-2023

Kalyan Banda MD, Assistant Professor, Division of Medical Oncology, University of Washington. Research and career mentor, member of Faculty Mentorship Committee: Molecular predictors of therapeutic response in breast and ovarian cancer. 2018-present.

Shaveta Vinayak MD, MS, Associate Professor in Medical Oncology, University of Washington: faculty mentor in translational research of breast cancer and DNA repair, 2018-2022.

T. Rinda Soong MD, PhD, Assistant Professor, Department of Pathology, University of Washington and University of Pittsburgh. Mentor on Rivkin Scholar Award 2020-2022 and primary mentor on Department of Defense Ovarian Cancer Academy Award, 2023-present.

Vida Henderson PhD, Fred Hutchinson Cancer Center, Member of Faculty Mentorship Committee, 2022-2025

Isabel Rodriguez MD, Acting Assistant Professor, Division of Gynecologic Oncology, Department of Ob/Gyn, Constitutional methylation and risk of cancer and use of HRDefine to predict response to PARP inhibition. WRHR Scholar mentor, 2025-present

Naoka Sasamoto MD, PhD, Assistant Professor, Public Health Division, Member of Faculty Mentorship Committee, 2025-present

Bill Howard PhD, Associate Professor, Department of Chemistry & Biochemistry, University of Alaska Fairbanks, Mentor for NIH R16 SuRE-First award. 2025-present

### **EDITORIAL RESPONSIBILITIES**

2012-2017	<i>Gynecologic Oncology</i> , Editorial Board
2012-2013	Guest Editor, <i>Gynecologic Oncology</i> special issue on Genomic Science and Individualized Medicine in Gynecologic Malignancies Volume 128, Issue 3, March 2013
2013-2014	Guest Editor, Proceedings of the National Academy of Sciences

### **AD HOC REVIEWER**

American Journal of Obstetrics and Gynecology  
Annals of Oncology  
BMC Cancer  
British Journal of Cancer  
Cancer  
Cancer Discovery  
Cancer Prevention Research  
Cell  
Cell Reports Medicine  
Clinical Cancer Research  
Epigenomics  
Genetics in Medicine  
Gynecologic Oncology  
International Journal of Cancer  
JAMA Oncology  
Journal of Clinical Investigation  
Journal of Clinical Oncology  
Journal of the National Comprehensive Cancer Network  
Journal of the National Cancer Institute  
Molecular Cancer Research  
Nature Communications  
Nature Medicine  
New England Journal of Medicine  
PLOS Genetics  
PLOS Medicine  
Proceedings of the National Academy of Sciences  
Science  
Science Translational Medicine

### **CLINICAL ACTIVITIES**

My cFTE is currently 15%. I have a weekly clinic at Fred Hutch Cancer Center focusing on the treatment of gynecological cancer patients with recurrent or metastatic disease with a focus on precision medicine. I have a clinical focus on therapeutic trials, including phase 1 and investigator-initiated trials. I participate in a multi-disciplinary clinic for the Breast and Ovarian Cancer Prevention Program which I founded at the Fred Hutch Cancer Center over 20 years ago, and I also actively participate in weekly tumor board and monthly molecular tumor board.

### **CURRENT RESEARCH SUPPORT**

NIH NCI P30 CA015704-49 Lynch (PI) 5/1/2024-4/30/2026 (subaward period)

Implementing HPV Self-Swab For Cervical Cancer Screening In A Community-Based Addiction Recovery Clinic

Role: sub-award PI

Cervical cancer is a preventable cancer caused by the human papilloma virus (HPV) that disproportionately impacts underserved populations. HPV self-testing is an acceptable screening alternative. In this pilot, we partner with the We Care Daily Clinics (WCDC), which serves individuals with opioid use disorder (OUD), to bring HPV self-testing to a vulnerable and under-screened population at increased risk for cervical cancer. \$200,000 (subaward direct costs)

Department of Defense, Ovarian Cancer Research Program Investigator Initiated Research Award

OC230256

Risques (PI)

5/1/2024-4/30/2026

Determining the Role of Somatic Mosaicism in Ovarian Cancer Predisposition

Role: Co-I

This study will test the hypothesis that a subset of ovarian cancers are driven by methylation or mutation in ovarian cancer susceptibility genes (eg, BRCA1, BRCA2, and others) in individual that are mosaic carriers, who can be detected by interrogating blood and normal tissues with ultra-accurate detection methods  
\$599,498 (total direct costs)

Rivkin Center/CARE Fund Award Swisher (PI) 41/2024-3/31/2026  
Optimizing genetic testing uptake and outcomes for hereditary ovarian cancer risk  
In this study, we will discover reasons for non-completion of cancer genetic testing by interviewing people who did not complete testing and by analyzing data on associated factors in the MAGENTA trial.  
\$147,809 (total direct costs)

NIH NCI U01 CA272607-01 Kemp (PI) 9/1/2023-6/30/2028  
A Patient-Centric Approach to Advance Functional Precision Oncology  
Role: Co-I  
\$622,000 (Sub-contract, total direct costs)  
This proposal is focused on identifying novel targets and potentially effective drugs to address drug resistant ovarian, pancreatic and other cancers, with improved patient outcomes as the ultimate benchmark

NIH NCI R01 CA272594-01A1 Swisher (PI) 5/1/2023-4/30/2028  
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer  
The goal is to determine how therapy-related myeloid neoplasia (TMN) develops in ovarian cancer patients and to identify strategies to prevent the onset of these aggressive secondary malignancies.  
Role: PI  
\$2,499,995 (total direct costs)

GOG Foundation Swisher (PI) 2/1/2021-1/31/2026  
*BRCA1 and RAD51C methylation and BRCA1 protein expression in GY004, a Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.*  
The objective is to correlate BRCA1 and RAD51C methylation status and BRCA1 protein expression with outcomes according to treatment arm.  
Role: PI  
\$302,500 (total direct costs)

GOG Foundation Swisher (PI) 2/1/2021-1/31/2026  
*BRCA1 and RAD51C methylation and BRCA1 protein expression in GY005, a Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or –refractory ovarian, fallopian tube, or primary peritoneal cancer.*  
The objective is to correlate BRCA1 and RAD51C methylation status and BRCA1 protein expression with outcomes according to treatment arm.  
Role: PI  
\$374,000 (total direct costs)

NIH NCI 5 P30 CA015701 Lynch (PI) 1/1/1997-12/31/2029  
Cancer Center Support Grant (CCSG)  
This grant supports research infrastructure that enhances collaborative, transdisciplinary research productivity in the cancer center.  
Role: Deputy Director and Program Co-leader (Breast and Ovarian Cancer Research Program)

K12 HD0011264 Goff (PI) 7/1/99-6/30/2030\*  
Women's Reproductive Health Research at the University of Washington  
This grant supports career development and research support for early Ob/Gyn clinician scientist faculty.  
\$1,575,000 (total direct costs)

Role: Research Director

GlaxcoSmithKline Swisher (PI) 4/1/21-ongoing  
Phase IB Trial of Niraparib and Dostarlimab (TSR-042) in patients with BRCA-mutated breast, pancreas or  
ovary cancer

This is an investigator-initiated clinical trial in BRCA mutated breast, pancreatic and ovarian cancer combining  
the PARP inhibitor niraparib and the PD-1 immune checkpoint inhibitor dostarlimab with pre-treatment an on-  
treatment biopsies.

Role: PI  
\$516,971

### **PAST RESEARCH SUPPORT**

Sloan Precision Oncology Institute Ignition Award Swisher (PI) 11/01/2024-10/31/2025  
Launching a multiplex BRCA1/RAD51C ddPCR methylation assay as a clinical HRD test  
\$75,000 (total direct costs)

NIH NCI U01 CA232795-01 Swisher (PI) 9/20/2019-8/31/2025  
*Implementing the moon: Getting genomic testing to the public*

This project will test two methods of engagement of patients in clinics from two different healthcare systems, to  
implement population-level genetic testing. It will follow patients and providers after the implementation period  
to determine lasting effects and negative effects.

Role: PI  
\$4,098,161 (total direct costs)

NIH NCI R01 CA237600-01A1 Swisher (PI) 4/1/2020-3/31/2025  
*Combined Methylation and Mutation to Predict Response to PARP Inhibitors*

The goal of this revised proposal is to develop a clinically useful predictor of PARP inhibitor beyond *BRCA*  
mutations that predict sensitivity/resistance to PARP inhibitors in order to spare toxicities and cost for ovarian  
cancer patients unlikely to derive benefit. The test will combine mutation analysis with a newly developed  
quantitative assay for BRCA1 and RAD51C methylation and will validate the assay across 4 large phase 3  
randomized controlled trials in ovarian cancer.

Role: PI  
\$1,954,861 (total direct costs)

NIH NCI R01 CA251817-01 Swisher (PI) 9/1/2020-5/31/2024  
*Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy*

The goal is to validate mutation and methylation analysis as a predictor of PARPi response in the randomized  
controlled trial ATHENA for primary treatment of advanced OC.

Role: PI  
\$920,451 (total direct costs)

GlaxcoSmithKline Swisher (local PI) 7/1/2018-10/1/2025

FIRST: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with  
TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line  
Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Role: Local PI

NIH NCI U01 CA217883-01 Kemp (PI) 9/1/2017- 8/31/2022  
*Personalized cancer models to discover and develop new therapeutic targets*

The goal of this grant is to identify new targets or effective drug/drug combinations using ovarian cancer cells  
(mostly HGSOE) as part of the NIH.NCI/USDHHS Cancer Target Discovery and Development Network  
(CTDD).

Role: Co-investigator

NIH/NCI/CTEP P17045 MOD02 (P9825 / P9881) Swisher (PI) 10/1/2016-12/31/2024  
*BROCA-HR Sequencing for Cediranib/Olaparib CTEP Clinical Development Program.*  
 Objective is to provide translational research support and characterize homologous recombination repair phenotype in 12 clinical trials for different cancer types in the CTEP developmental therapeutics program for cediranib and olaparib.  
 Role: PI, designated CTEP core lab  
 \$1,404,000 (total direct costs)

NIH K08 CA222385 Yu (PI) 3/1/2018-2/28/2023  
 The role of the fallopian tube microbiome in ovarian carcinogenesis  
 Role: Mentor (no salary support)

Elucida Oncology Swisher (local PI) 7/1/2023-9/1/2024  
 Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FR $\alpha$  overexpressing tumors  
 Role: Local PI

GOG Foundation Swisher (PI) 2/1/2016-1/31/2022  
*BROCA-HR sequencing for A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or –refractory ovarian, fallopian tube, or primary peritoneal cancer.*  
 The objective is to correlate outcomes according to treatment arm with germline and somatic mutations in homologous recombination repair genes and assess a measure of genomic scarring consistent with homologous recombination deficiency.  
 Role: PI for translational research GY005  
 \$408,000 (total direct costs)

cell free DNA RFI Swisher (PI) 1/1/2019-12/31/2021  
*Mutational signatures in WGS of cell free plasma DNA*  
 The goal of this Brotman Baty Institute (BBI) Award is to identify mutator signatures in cfDNA whole genome sequencing that identify defects in homologous recombination DNA repair and thus predict response to PARP inhibitors.  
 BBI is providing cfDNA sequencing for 50 samples. There will be no exchange of funds for this award.

Department of Defense, Ovarian Cancer Research Program Clinical Development Award  
 OC160274 Swisher (PI) 3/1/2017-7/31/2021  
*Mutator Phenotypes that Better Predict PARP Inhibitor Response in Ovarian Carcinomas*  
 The goal of this proposal is to identify mutator signatures characteristic of homologous recombination deficiency in tumors samples from patients on the PARP inhibitor trial ARIEL2, part 1 in order to develop a better clinical test for identifying patients who will respond to PARP inhibitors compared to currently available assays that depend on assessment of allelic imbalance.  
 Role: Principal Investigator  
 \$600,000 (total direct costs)

Department of Defense, Ovarian Cancer Research Program Investigator Initiated Research Award  
 OC160355 Swisher (PI) 3/1/2017-7/31/2021  
*Real-Time Assessment of Homologous Recombination Deficiency during Ovarian Cancer Treatment*  
 The goal of this proposal is to develop 1. A sequencing assay for somatic BRCA reversion mutations and 2. a homologous recombination assessment in cell-free plasma DNA to allow noninvasive monitoring of DNA repair capacity in cancer during the course of treatment.  
 Role: Principal Investigator  
 \$450,000 (total direct costs)

NIH/NCI R35 CA197458 King (PI) 08/01/2015-07/30/2022

*Genomic Analysis of Inherited Breast and Ovarian Cancer*

The goal of this Outstanding Investigator Award is to bring genomic analyses to bear on the question of inherited breast and ovarian cancer.

Role: Co-Investigator

\$4,200,000 (total direct costs)

Clovis Oncology Swisher (PI) 2014-2022

*ARIEL3: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer.*

Role: Principal Investigator

NIH NCI R01 CA190423 Kaufman (PI) 3/1/15 - 2/28/2020

*Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer*

The goal of this study is to identify various molecular alterations that explain PARP inhibitor resistance in patients with cancer

Role: Co-Investigator

\$240,000 (total direct costs)

American Association of Cancer Research, Stand Up To Cancer Ovarian Cancer Dream Team

SU2C-AACR-DT16-15 D'Andrea (Leader) 7/1/2015-6/30/2019

*DNA Repair Therapies for Ovarian Cancer*

The objective is to exploit DNA repair deficiencies in ovarian cancer to develop novel therapies and prevention strategies.

Role: Co-leader

\$6,000,000 (total costs)

GOG Foundation Swisher (PI) 2/1/2016-1/31/2019

*BROCA-HR sequencing for phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.*

The objective is to correlate outcomes according to treatment arm with germline and somatic mutations in homologous recombination repair genes and assess a measure of genomic scarring consistent with homologous recombination deficiency.

Role: PI for translational research GY004

\$270,000 (total direct costs)

Southwest Oncology Group S1513 Swisher (PI) 9/1/2016-2/28/2019

*BROCA-HR for randomized phase II study of 2<sup>nd</sup> Line FOLFIRI versus modified Folfiri with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) in metastatic pancreatic cancer*

The objective is to perform BROCA-HR analysis of germline and somatic DNA from pancreatic cancer patients treated with chemotherapy plus or minus PARP inhibitor to identify relationship of response to therapy and DNA repair defects.

Role: Co-PI of trial heading translational research

\$120,000 (total direct costs)

Southwest Oncology Group S1416 Swisher (PI) 6/1/2016-5/31/2019

*BROCA-HR for Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) In Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer*

The purpose is to coordinate the translational research on this trial and perform BROCA-HR sequencing of germline DNA from breast cancer patients treated with chemotherapy plus or minus PARP inhibitor to identify relationship of response to germline DNA repair defects and provide results to patients on the trial.

Role: Co-PI of trial heading translational research

\$150,000 (total direct costs)

Department of Defense, Ovarian Cancer Research Program Investigator Initiated Research Award  
OC140243 Swisher (PI) 4/15/2015-10/14/2018  
*Cancer Risks Associated with Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2*

The objective is to assess cancer risk associated with inherited loss of function mutations in ovarian cancer genes other than BRCA1 and BRCA2 by enrolling and testing families at high risk of hereditary ovarian cancer and to define the genes and frequency of hereditary ovarian cancer in African-American women.

Role: Principal Investigator

\$450,000 (total direct costs)

US Preventive Services Taskforce Devine (PI) 11/1/2016-6/30/2018  
*BRCA-Related Cancer: Risk Assessment, Genetic Counseling and Genetic Testing*

The objective is to review current data and create new USPSTF recommendations on risk assessment and genetic testing for BRCA1 and BRCA2 mutations and to update the national guidelines on this topic.

Role: Co-investigator

\$18,800 (total direct costs)

Clovis Oncology Swisher (PI) 2013-2018  
*ARIEL2: A Phase 2 Open-Label Study of Rucaparib in Patients with Platinum-Sensitive Relapsed High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.*

Role: North American Principal Investigator

STTR Precision Medicine Grant

Identification of Subtype-specific therapeutics targets in ovarian cancer through high-throughput small interference RNA (siRNA) screens with characterized patient derived tumor cells.

July 1, 2017-June 30, 2018 Kemp (PI)

Role: Co- Investigator

\$100,000 (total direct costs)

Marsha Rivkin Center for Ovarian Cancer Research, 2017  
Rivkin Pilot Award

*Characterization of TP53 mutations in BRCA carcinogenesis* Risques (PI) 4/1/2017-3/31/2018

The objective of this award is to determine if the number or frequency of TP53 mutations found in blood or normal tissue indicate a larger probability of cancer progression. If this was the case, then TP53 mutations in the blood could become a non-invasive biomarker to determine the risk of high grade serous ovarian carcinoma.

Role: Co-investigator

\$74,943 (total direct costs)

TESARO/GlaxcoSmithKline Swisher (local PI) 6/12/2017-7/1/2023  
GARNET, TSR-042 phase I/2 clinical trial

This is a phase 1 and 2 trial in endometrial cancer both with and without microsatellite instability of TSR-042, which is a PD-1 immune checkpoint inhibitor.

Role: UW PI

Plexxicon Swisher (local PI) 6/12/2017-12/31/22  
Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced *Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer*

Role: UW PI

Clovis Oncology Swisher (PI) 2014-2022

*ARIEL3: A Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed, High grade serous or Endometrioid Ovarian Cancer.*  
Role: Local Principal Investigator

V Foundation Translational Research Award Swisher (co-PI) 11/1/2013-10/31/2017  
*Defining genomic scarring and functional DNA variants that predict response to PARP inhibitors in a clinical trial for recurrent ovarian cancer.*  
The goal is to test various platforms to define a genomic scar in ovarian cancers that can predict response to PARP inhibition.  
Role: Co-Principal Investigator (with Toshiyasu Taniguchi MD PhD)  
\$900,000 (total direct costs)

Department of Defense, Ovarian Cancer Research Program Synergistic Translational Leverage Award  
OC120506 Swisher (PI) 9/1/2013-8/31/2016  
*Evaluation of DNA Repair Function as a Predictor of Response in a Clinical Trial of PARP Inhibitor Monotherapy for Recurrent Ovarian Carcinoma*  
The goal is to develop and test a biomarker that will predict sensitivity to PARP inhibitors in the context of a clinical trial in recurrent ovarian cancer.  
Role: Principal Investigator  
\$500,000 (total direct costs)

Arkansas Breast Cancer Program Zorn (PI) 2/3/2015-6/31/2016  
*Investigating the germline mutation rate in African-American women in Arkansas with a personal or family history of breast cancer using a multiplex panel*  
The goal is to evaluate the rate of inherited mutations in cancer susceptibility genes in African-American women with breast cancer or a family history of breast cancer.  
Role: Co-Investigator  
\$175,000 (total direct costs)

Ovarian Cancer Research Fund Swisher (PI) 1/1/2013-12/31/2015  
*The FA-BRCA pathway response to platinum and PARP inhibitors in ovarian, tubal and peritoneal carcinomas*  
Program Project Development Grant  
The objective is to develop a biomarker of cancer response to PARP inhibitor therapy using banked specimens and xenografts.  
Role: Principal Investigator  
\$900,000 (total costs)

Department of Defense, Ovarian Cancer Research Program Pilot Award  
OC120312 Swisher (PI) 9/1/2013-8/31/2015  
*The Fanconi Anemia BRCA Pathway As A Predictor Of Benefit From Bevacizumab In A Large Phase III Clinical Trial In Ovarian Cancer*  
The goal is to evaluate known and candidate ovarian cancer susceptibility in a large clinical trial and relate mutation status to patient outcomes to determine if women wildtype for mutation in the Fanconi anemia pathway derive more benefit from the addition of bevacizumab to standard therapy.  
Role: Principal Investigator  
\$250,000 (total direct costs)

NIH NCI Ovarian SPORE P50 CA83636 Urban (PI) 7/1/2009-9/30/2014  
*Clinical implication of the acquisition of BRCA1/2 function in BRCA1/2-deficient ovarian carcinoma*  
Pacific Ovarian Cancer Research Consortium  
The goal of this project is to determine the clinical relevance of restoration of BRCA1/2 in BRCA1/2-deficient hereditary and sporadic ovarian carcinomas.  
Role: Co-Leader Project 4  
\$375,000 (subcontract)

NIH NCI 1R01 CA131965-01 Swisher (PI) 5/8/2009-2/28/2014  
*Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium*  
The goal is to identify a premalignant phenotype in the fallopian tube epithelium that may be a precursor to ovarian carcinoma in women with inherited BRCA1 mutations.  
Role: Principal Investigator  
\$1,037,500 (total direct costs)

Department of Defense, IDEA Development Award Walsh (PI) 3/1/2010-3/31/2013  
*Whole Genome Sequencing to Identify Novel Ovarian Cancer Genes*  
The goal is to identify novel ovarian cancer genes using next generation sequencing technologies.  
Role: Co-Investigator  
\$375,000 (total direct costs)

The Mary Kay Foundation Swisher (PI) 6/1/2010-12/30/2012  
*BRCA1/2 Restoration as a Predictor of Response in a GOG Clinical Trial for Recurrent Ovarian Carcinoma*  
Cancer Research Grant  
The goal is to evaluate the BRCA1 pathway in primary and recurrent paired tumors and the relationship to clinical response.  
Role: Principal Investigator  
\$100,000 (total costs)

NIH NCI R01CA125616-03 Taniguchi (PI) 7/1/2007-6/30/2012  
*The Fanconi Anemia-BRCA Pathway and Chemosensitivity of Human Cancer*  
The goals of this study are to define the role of the Fanconi Anemia-BRCA pathway in the chemoresistance of ovarian cancer and to define modulators of that pathway.  
Role: Co-investigator  
\$180,278 (total direct costs)

AbbVie Swisher (PI) 2013-2014  
*A Phase I Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects with Solid Tumors*  
Role: Principal Investigator

Marsha Rivkin Center for Ovarian Cancer Research Norquist (PI) 4/1/2013-3/31/2014  
*Genes Contributing to Ovarian Cancer in BRCA1/2 Wildtype Families*  
Scientific Scholar Award  
Role: Mentor  
\$60,000 (total costs)

Marsha Rivkin Center for Ovarian Cancer Research Swisher (PI) 6/1/2009-5/30/2012  
*Fallopscopy: A Novel Approach to Ovarian Cancer Detection and Prevention*  
Role: Principal Investigator  
\$75,000 (total costs)

Department of Defense, Translational Research Award Swisher (PI) 7/1/2008-6/30/2011  
*Premalignant Genetic and Epigenetic Alterations in Tubal Epithelium from Women with BRCA1 Mutations*  
Role: Principal Investigator  
\$462,000 (total direct costs)

University of Washington/Fred Hutchinson Cancer Consortium Swisher (PI) 1/1/2008-12/31/2008  
*Characterization of Microparticles in Ovarian Carcinoma Ascites*  
Role: Principal Investigator  
\$40,000 (total direct costs)

University of Washington Bridging Funds	Swisher (PI)	10/01/2007-9/30/2008
<i>Defining a Premalignant Phenotype in Ovarian and Tubal Epithelium</i>		
Role: Principal Investigator		
\$49,338 (total direct costs)		
NIH NCI K08 CA96610	Swisher (PI)	10/01/2002-9/30/2007
<i>Genetic and Epigenetic Markers in Ovarian Cancer</i>		
Role: Principal Investigator		
\$657,000 (total costs)		
Ovarian Cancer Research Fund	Swisher (PI)	1/1/2005-12/31/2006
<i>Angiogenic Alterations Leading to Circulating Tumor DNA in Women with Ovarian Cancer</i>		
Role: Principal Investigator		
\$50,000 (total direct costs)		
Eli Lilly, Investigator Initiated Protocol	Swisher (PI)	2003-2006
<i>Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: A phase I trial of the Puget Sound Oncology Consortium</i>		
Role: Principal Investigator		
University of Washington/Fred Hutchinson Cancer Consortium	Swisher (PI)	1/1/2005-12/31/2005
<i>Tumor-specific p53 Mutations in Blood, Peritoneal Fluid and Pap Smears of Women with Ovarian Cancer</i>		
Role: Principal Investigator		
\$40,000 (total direct costs)		
University of Washington/Fred Hutchinson Cancer Consortium	McGregor (PI)	1/1/2005-12/31/2005
<i>Prophylactic Oophorectomy Surgery and Quality of Life among Women at Elevated Risk for Ovarian and Breast Cancer</i>		
Role: Co-Investigator		
\$25,000 (total direct costs)		
Kimmel Scholar Award	Swisher (PI)	7/1/2002-6/30/2005
<i>Molecular Markers for Ovarian Cancer</i>		
Sidney Kimmel Foundation for Cancer Research		
Role: Principal Investigator		
\$200,000 (total costs)		
Pacific Ovarian Cancer Research Consortium Pilot Award	Swisher (PI)	4/1/2004-3/31/2005
<i>Gene Expression in High-risk Ovarian Surface Epithelium</i>		
Role: Principal Investigator		
\$45,511 (total direct costs)		
Florence & Marshall Schwid Ovarian Cancer Grant	Swisher (PI)	1/1/2001-12/31/2001
<i>Impact of epigenetic modulation of DNA repair genes on chemoresistance and survival in ovarian cancer.</i>		
Gynecologic Cancer Foundation		
Role: Principal Investigator		
\$50,000 (total direct costs)		
National Institute of Health K12	Soules (PI)	7/1/1999-10/1/2002
<i>Womens Reproductive Health Research Training Grant</i>		
Role: WRHR Scholar		

**LICENSES/PATENTS**

**BIBLIOGRAPHY REFEREED ARTICLES**

1. **Swisher EM**, Shawler DL, Collins HA, Bustria A, Harts A, Bloomfield C, Miller RA, Royston I. Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. *Blood*. 1991 May;77(9):1977-82. PMID:1902123
2. Swisher SG, Schmit PJ, Hunt KK, Hiyama DT, Bennion RS, **Swisher EM**, Thompson JE. Biliary disease in pregnancy. *Am J Surg*. 1994 Dec;168(6):576-9. PMID:7977999
3. **Swisher EM**, Gown AM, Skelly M, Ek M, Tamimi HT, Cain JM, Greer BE, Goff BA. The expression of epidermal growth factor receptor, HER2/neu, p53, and MIB-1 in uterine malignant mixed mesodermal tumor and adenocarcinoma. *Gynecol Oncol*. 1996 Jan;60(1):81-8. PMID:8557233
4. **Swisher EM**, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel -resistant ovarian cancer. *Gynecol Oncol*. 1997 Sep;66(3):480-6. PMID:9299264
5. **Swisher E**, Drescher CW. Metastatic placental site trophoblastic tumor: Long term remission in a patient treated with EMA/CO chemotherapy. *Gynecol Oncol*. 1998 Jan;68(1):62-5. PMID:9454662
6. **Swisher EM**, Mutch DG, Herzog TJ, Rader JS, Kowalski LD, Elbendary A, Goodfellow PJ. Analysis of MSH3 in endometrial cancers with defective DNA mismatch repair. *J Soc Gynecol Investig*. 1998 Jan;5(4):210-6. PMID:9699180
7. **Swisher EM**, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Differences in the pattern of *TP53* and *KRAS2* mutations in a large series of endometrial cancers characterized for microsatellite instability. *Cancer*. 1999 Jan;85(1):119-26. PMID:9921983
8. Simpkins SB, Bocker T, **Swisher EM**, Mutch DG, Gersell DJ, Kovatich AJ, Palazza JP, Fishel R, Goodfellow PJ. MLH1 promoter methylation and gene silencing is the primary cause of MSI in sporadic endometrial cancers. *Hum Mol Genet*. 1999 April;8(4):661-6. PMID:10072435
9. Basil JB, **Swisher EM**, Herzog TJ, Rader JS, Elbendary A, Mutch DG, Goodfellow PG. Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability. *Gynecol Oncol*. 1999 Sep;74(3):395-9. PMID:10479499
10. Cohn DE, **Swisher EM**, Herzog TJ, Rader JS, Mutch DG. Radical hysterectomy for cervical cancer in obese women. *Obstet Gynecol*. 2000 Nov;96(5):727-31. PMID:11042308
11. Paley PJ, **Swisher EM**, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA. Occult cancer of the fallopian tube in BRCA-a germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. *Gynecol Oncol*. 2001 Feb;80:176-80. PMID:11161856
12. **Swisher E**. Hereditary cancers in obstetrics and gynecology. *Clin Obstet Gynecol*. 2001 Sep;44(3):450-63. PMID:11685871
13. **Swisher EM**, Babb S, Whelan A, Mutch DG, Rader JS. Prophylactic oophorectomy and ovarian cancer surveillance: patient perceptions and satisfaction. *J Reprod Med*. 2001 Feb;46(2):87-94. PMID:11255821
14. Herzog TJ, Kowalski LD, Liu H, Arlt M, **Swisher E**. Evaluation of a region on chromosome 1P in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma. *Gynecol Oncol*. 2001 July;82(1):139-42. PMID:11426975

15. **Swisher EM**, Cohn DE, Goff BA, Parham J, Herzog TJ, Rader JS, Mutch DG. Use of complementary and alternative medicine among women with gynecologic cancers. *Gynecol Oncol.* 2002 March;84(3):363-7. PMID:11855870
16. Babb SA, **Swisher EM**, Heller HN, Whelan AJ, Mutch DG, Herzog TH, Rader JS. Qualitative evaluation of medical information processing needs of 60 women choosing ovarian cancer surveillance or prophylactic oophorectomy. *J Genet Couns.* 2002 April;11(2):81-96. PMID:26141655
17. Welch P, Lee M, Gonzalez-Hernandez R, Black D, Mahadevappa M, **Swisher E**, Warrington J, King MC. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. *Proc Natl Acad Sci USA.* 2002 May 28;99(11):7560-5. PMID: 124283. PMCID: PMC124283
18. Leeper K, Garcia R, **Swisher E**, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. *Gynecol Oncol.* 2002 Oct;87(1): 52-6. PMID:12468342
19. Goodfellow PJ, Buttin BM, Herzog TH, Rader JS, Gibb RK, **Swisher E**, Look K, Walls KC, Fan MY, Mutch DG. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. *Proc Natl Acad Sci USA.* 2003 May;100(10):5908-13. PMID: 156300. PMCID: PMC156300
20. **Swisher EM.** Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer. *Curr Treat Options Oncol.* 2003 Apr;4(2):105-10. PMID:12594936
21. Everett E, Tamimi H, Greer B, **Swisher E**, Paley P, Mandel L, Goff B. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. *Gynecol Oncol.* 2003 July;90(1):150-7. PMID:12821356
22. Agoff SN, Garcia RL, Goff B, **Swisher E.** Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA1 or BRCA2 mutations. *Am J Surg Pathol.* 2004 Aug;28(8):1112-4. PMID:15252324
23. **Swisher E**, Wollan M, Mahtani S, Willner J, Garcia R, Goff B, King MC. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. *Am J Obstet Gynecol.* 2005 Sep;193(3):662-7. PMID:16150257
24. Shah C, Johnson EB, Everett E, Tamimi H, Greer B, **Swisher E**, Goff B. Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer. *Gynecol Oncol.* 2005 Dec;99(3):564-70. PMID:16246402
25. **Swisher EM**, Swensen RE, Greer BE, Tamimi H, Goff BA, Garcia G, Koh W. Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium. *Gynecol Oncol.* 2006 June;101(3):429-35. PMID:16337995
26. Lachance JA, Everett EN, Greer B, Mandel L, **Swisher E**, Tamimi H, Goff B. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. *Gynecol Oncol.* 2006 June;101(3):470-5. PMID:16413048
27. Walsh T, Casadei S, Coats KH, BS, **Swisher E**, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King, MC. Spectrum of mutations in *BRCA1*, *BRCA2*, *CHEK2*, and *TP53* in families at high risk of breast cancer. *JAMA.* 2006 March;295(12):1379-88. PMID:16551709
28. Lamb JD, Garcia RL, Goff BA, Paley PP, **Swisher EM.** Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. *Am J Obstet Gynecol.* 2006 June;194(6):1702-9. PMID:16731090

29. Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray, H, **Swisher EM**. Common polymorphism in Interleukin 6 influences survival of women with advanced stage ovarian and peritoneal carcinoma. *Gynecol Oncol*. 2006 Dec;103(3):793-6. PMID: 17023036 PMCID: PMC2562602
30. Hartwell L, Mankoff D, Paulovich A, Ramsey S, **Swisher EM**. Cancer biomarkers: a systems approach. *Nat Biotechnol*. 2006 Aug;24(8):905-8. PMID:16900126
31. Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray H, **Swisher EM**. Common polymorphisms in p53 and MDM2 in women with ovarian and peritoneal carcinomas; relationship to p53 mutations and clinical outcomes. *Genes, Chromosomes Cancer*. 2007 March;46(3):239-47. PMID:17171684
32. DelloRusso C, Welcsh PL, Weixin W, Garcia R, King MC, **Swisher EM**. Functional characterization of a novel *BRCA1*-null ovarian cancer cell line in response to ionizing radiation. *Mol Cancer Res*. 2007 Jan;5(1):35-45. PMID:17259345
33. Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, **Swisher EM**. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. *Human Pathol* 2007 April;38(4):607-13. PMID:17258789
34. Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, **Swisher EM**, Crowder S, Li J, Gerhard DS, and Rader JS. *CD83* gene polymorphisms increase susceptibility to human Invasive cervical cancer. *Cancer Res*. 2007 Dec;67:11202-8. PMID:18056445
35. Brotto LA, Heiiman JR, Goff B, Greer B, Lentz GM, **Swisher E**, Tamimi H, VanBlaricom A. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. *Arch Sex Behav*. 2008 April;37(2):317-29. PMID:17680353
36. Sakai W, **Swisher EM**, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in *BRCA2*-mutated cancers. *Nature*. 2008 Feb;451:1116-20. PMID: 18264087. PMCID: PMC2577037
37. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, **Swisher EM**. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. *Gynecol Oncol*. 2008 May;109(2):215-9. PMID:18314181
38. Allison KH, **Swisher EM**, Kerkering KM, Garcia RL. Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is a full staging procedure unnecessary? *Int J Gynecol Pathol*. 2008 Jan;27(1):10-17. PMID:18156968
39. Chisholm, KM, Goff BA, Garcia R, King MC, **Swisher EM**. Genomic structure of chromosome 17 deletions in *BRCA1* associated ovarian cancers. *Cancer Genet Cytogenet*. 2008 May;183(1):41-8. PMID: 18474296. PMCID: PMC2413294
40. **Swisher EM**, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary *BRCA1* mutations in *BRCA1*-mutated ovarian carcinomas with platinum resistance. *Cancer Res*. 2008 April;68(8):2581-6. PMID: 18413725. PMCID: PMC2674369
41. Fox KV, Shah CA, **Swisher EM**, Garcia RL, Mandel LS, Gray HJ, Swensen RE, Goff BA. An evaluation of cervical cancer in women age sixty and over. *Gynecol Oncol*. 2008 April;109(1):53-8. PMID:18255127

42. Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J, **Swisher E**, Zhang B, Ben-Baruch G, Tan MC, Goedegebuure P, Hellstrom KE. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. *Cancer Epidemiol Biomarkers Prev.* 2008 June;17(6):1520-6. PMID:18559570
43. Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, **Swisher EM**, Xi L, Drescher C, Urban N, Kiviat NB. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. *Gynecol Oncol.* 2008 Nov;111(2):320-9. PMID:18757082
44. Allison KH, Tennpenny E, Reed SD, **Swisher EM**, Garcia RL. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. *Appl Immunohistochem Mol Morphol* 2008 Jul;16(4):329-43. PMID:18528284
45. Reed SE, Voigt LF, Newton KM, Garcia RH, Allison HK, Epplein M, Jordan D, **Swisher EM**, Weiss NS. Progestin therapy of complex endometrial hyperplasia with and without atypia. *Obstet Gynecol.* 2009 March;113(3):665-2. PMID: 19300331. PMCID: PMC2680496
46. **Swisher EM**, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, Welcsh P. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. *Mol Cancer.* 2009 July;8:48. PMID: 19602291. PMCID: PMC2719582
47. Sakai W, **Swisher EM**, Jacquemont C, Chandramohan KV, Couch FJ, Landon SP, Wurz K, Higgins J, Villegas E, Taniguchi T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. *Cancer Res.* 2009, Aug;69(16): 6381-6. PMID: 19654294. PMCID: PMC2754824
48. Wurz K, Garcia RL, Goff BA, Mitchell PS, Lee JH, Tewari M, **Swisher EM**. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKN1C and overall survival. *Genes Chromosomes Cancer.* 2010 Jul;49(7):577-84. PMID: 20461750. PMCID: PMC2869465
49. Hellstrom I, Heagerty PJ, **Swisher EM**, Liu P, Jaffar J, Agnew K, Hellstrom KR. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. *Cancer Lett.* 2010 Oct;296(1):43-8. PMID: 20381233. PMCID: PMC3156592
50. Norquist B, Garcia R, Allison K, Jokinen C, Kernochan L, Pizzi C, Barrow B, **Swisher E**. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with *BRCA1* and *BRCA2* mutations. *Cancer.* 2010 Nov;116(22):5261-71. PMID: 20665887. PMCID: PMC2975783
51. Reed SD, Newton KM, Garcia RL, Allison KH, Vogt LF, Jordan CD, Epplein M, **Swisher EM**, Upson K, Ehrlich KJ, Weiss NS. Complex hyperplasia with and without atypia – clinical outcomes and implications of progestin therapy in a 20-year cohort study of 1443 women. *Obstet Gynecol.* 2010 Aug;116(2):365-73. PMID: 20664397. PMCID: PMC2949551
52. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, **Swisher EM**, King MC. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. *Proc Natl Acad Sci USA.* 2010 Jul;107(28):12629-33. PMID: 20616022. PMCID: PMC2906584
53. Ibrahim N, He L, Leong CO, Xing D, Karlan BY, **Swisher EM**, Rueda BR, Orsulic S, Ellisen LW. *BRCA1* associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. *Cancer Res.* 2010 Sept;70(18):7155-65. PMID: 20807817. PMCID: PMC2940979

54. Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, Welch P, Goff BA, **Swisher EM**. Identification of a premalignant gene expression profile in tubal epithelium of *BRCA1* mutation carriers. *Neoplasia*. 2010 Dec;12(12):993-1002. PMID: 21170264.PMCID: PMC3003134
55. **Swisher EM**. Editorial. Granulin: biomarker or interesting window into host/tumor biology? *Gynecol Oncol*. 2011 Jan;120(1):1-2. PMID: 21130922
56. Dhillon KK, **Swisher EM**, Taniguchi T. Secondary mutations of *BRCA1/2* and drug resistance. *Cancer Sci*. 2011 Apr;102(4):663-9. PMICD: PMC3095365
57. Norquist B, Wurz K, Pennil CC, Garcia R, Gross J, Sakai W, Karlan B, **Swisher EM**. Secondary somatic mutations restoring *BRCA1/2* predict chemotherapy resistance in hereditary ovarian carcinomas. *J Clin Oncol*. 2011 Aug;29(22):3008-15. PMID: 21709188. PMCID: PMC3157963
58. Knouf E, Garg K, Arroyo J, Correa Y, Sarkar D, Parkin R, Wur K, O'Briant KI, Godwin A, Urban N, Ruzzo W, Gentleman R, Drescher C, **Swisher E**, Tewari M. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. *Nucleic Acids Res*. 2012 Jan;40(2):499-510. PMICD: PMC3258134
59. \*Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, **Swisher EM**. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci USA*. 2011 Nov;108(44):18032-7. PMID: 22006311. PMCID: PMC3207658  
\*This work was selected as the Genome Advance of the Month, National Human Genome Research Institute, Jan 2012
60. Press JZ, Reyes M, Pitteri AJ, Garcia RL, Goff BA, Hanash S, **Swisher EM**. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. *Int J Gynecol Cancer*. 2012 May;22(4):546-52. PMID:22315094
61. Pennington KP, **Swisher EM**.Hereditary ovarian cancer: beyond the usual suspects. *Gynecol Oncol*. 2012 124(2):347-53. PMID: 22264603
62. **Swisher E**, Walsh T. *BRCA1* and *BRCA2* mutations in ovarian cancer. *JAMA*. 2012 25;307(4):359-60. PMID: 22274679
63. Wei H, Liu P, **Swisher E**, Yip YY, Tse JH, Agnew K, Hellström KE, Hellström I. Silencing of the *TGF-β1* gene increases the immunogenicity of cells from human ovarian carcinoma. *J Immunother*. 2012 Apr;35(3):267-75. PMID: 22421944. PMCID: PMC3327124
64. Allison KH, Upson K. Reed SD, Jordan CD, newton KM, Doherty J, **Swisher EM**, Garcia RL. *PAX2* loss by immunohistochemistry occurs early and often in endometrial hyperplasia. *Int J Gynecol Pathol*. 2012 Mar;31(2):151-9. PMID: 22317873. PMCID: PMC4646427
65. Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, **Swisher EM**, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, Tait JF, Walsh T. *ColoSeq* Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing. *J Mol Diagn*. 2012 Jul;14(4):357-66. PMID: 22658618. PMCID: PMC3391416

66. Vogel TJ, Stoops K, Bennett RL, Miller M, **Swisher EM**. A self-administered family history questionnaire improves identification of women who warrant referral to genetic counseling for hereditary cancer risk. *Gynecol Oncol*. 2012 Jun;125(3):693-8 PMID:22446623
67. **Swisher EM**, Taniguchi T, Karlan BY. Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. *J Natl Cancer Inst*. 2012 May;104(9):642-5. PMID: 22505475. PMCID: PMC3341312
68. Upson K, Allison KH, Reed SD, Jordan CD, Newton KM, **Swisher EM**, Doherty JA, Garcia RL. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. *Am J Obstet Gynecol*. 2012 Jul;207(1):36.e1-8. PMID: 22727345. PMCID: PMC3398620
69. Vogel TJ, DelloRusso C, Welch P, Shah CA, Goff BA, Garcia RL, **Swisher EM**. Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma. *Trans Oncology*. 2012 Aug;5(4):247-51. PMICD: PMC3431034
70. Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, **Swisher E**, Kivita NB, Feng Q. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. *World J Surg Oncol*. 2012 Aug 27;10:174. PMID: 22925189. PMCID: PMC3449188
71. Smith NL, Welch P, Press JZ, Agnew KA, Garcia R, **Swisher EM**. E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium. *Genes Chromosomes Cancer*. 2012 Nov;51(11):1054-62. PMID: 22887716. PMCID: PMC6816467
72. Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King MC, Goodfellow P, **Swisher EM**. BRCA1, TP53 and CHEK2 germline mutations in uterine serous carcinoma. *Cancer*. 2013 Jan;119(2):332-8. PMID: 22811390. PMCID: PMC3966566
73. Wickramanayake A, Bernier G, Pennil C, Casadei S, Agnew KJ, Stray SM, Mandell J, Garcia RL, Walsh T, King MC, **Swisher E**. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. *Gynecol Oncol*. 2012 Dec;127(3):552-5. PMICD: PMC3905744
74. Powell CB, **Swisher EM**, Cass I, McLennan J, Norquist B, Garcia RL, Lester J, Karlan BY, Chen L. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. *Gynecol Oncol*. 2013 May;129(2):364-71. PMID: 23391663. PMCID: PMC6853713
75. Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, **Swisher EM**. Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. *Gynecol Oncol*. 2013 Mar;128(3):483-7. PMID: 23262210. PMCID: PMC3913382
76. Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welch P, **Swisher EM**. 53BP1 expression in sporadic and inherited ovarian carcinoma: relationship to genetic status and clinical outcomes. *Gynecol Oncol*. 2013 Mar;128(3):493-9. PMID: 23246380. PMCID: PMC3889639
77. Rybeck B, Reed E, Petros W, McManus T, Hays KE, **Swisher E**, Hebert MF. Duration of cisplatin excretion in breast milk: a case report. *J Hum Lact*. 2013 Nov;29(4):469-72. PMID: 23492761. PMCID: PMC4041270

78. Hellstrom I, **Swisher E**, Hellstrom KE, Yip YY, Agnew K, Luborsky JL. Anti-HE4 antibodies in infertile women and women with ovarian cancer. *Gynecol Oncol*. 2013 Sep;130(3):629-33. PMID: PMC3748160
79. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, **Swisher E**. Cowden syndrome and the PTEN Hamartoma Tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst*. 2013 Nov;105(21):1607-16. PMID: 24136893
80. Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell M, Liu JF, D'andrea AD, Miron A, **Swisher EM** Shapiro GI. Stabilization Of Mutant BRCA1 Confers Parp Inhibitor And Platinum Resistance. *Proc Natl Acad Sci USA*. 2013 Oct 15;110(42):17041-6. PMID: 24085845. PMID: PMC3801063
81. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Isaksson Vogel R, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, Shridhar V, Bell DA, April C, Bentley D, Bibikova M, Cheetham RK, Fan JB, Grocock R, Humphray S, Kingsbury Z, Peden J, Chien J, **Swisher EM**, Hartmann LC, Kalli KR, Goode EL, Scotte H, Kaufmann SH, Harris RS. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. *Cancer Res*. 2013 Dec15;73(24):7222-31. PMID: 24154874. PMID: PMC3867573
82. Kissel HD, Paulson TG, Liu K, Li X, **Swisher E**, Garcia R, Sanchez CA, Reid BJ, Reed SD, Doherty JA. Feasibility of RNA and DNA Extraction from Fresh Pipelle and Archival Endometrial Tissues for Use in Gene Expression and SNP Arrays. *Obstet Gynecol Int*. 2013;2013:576842. PMID: 24282417. PMID: PMC3825122
83. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil C, Rendi M, Thornton A, Norquist BM, Casadei S, Nord A, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, **Swisher EM**. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. *Clin Cancer Res*. 2014 Feb 1;20(3):764-75. PMID: 24240112. PMID: PMC3944197
84. Topp M, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, **Swisher EM**, Bowtell DD, Wakefield, Scott CL. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. *Mol Oncol* 2014 May;8(3):656-68. PMID: 24560445. PMID: PMC4400120
85. Lorenz T, McGregor B, **Swisher E**. Relationship satisfaction predicts sexual activity following risk-reducing salpingo-oophorectomy. *J Psychosom Obstet Gynaecol*. 2014 June;35(2):62-8. PMID: 24693956. PMID: PMC4117249
86. Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SC, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, **Swisher E**, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. *J Natl Compr Canc Netw*. 2014 Sep;12(9):1326-38. PMID: 25190698
87. Tolcher MC, **Swisher EM**, Medeiros F, Lima JF, Hilderbrand JL, Donovan JL, Garcia RL, Cliby WA, Dowdy SC. Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma. *Int J Gynecol Pathol*. 2015 Jan;34(1):57-64. PMID: 25473754. PMID: PMC4405903

88. Morse CB, Garcia RL, Calhoun KE, **Swisher EM**. Premalignant alterations in breast and endometrium associated with a PTEN mutation in a woman with Cowden syndrome: implications for preventive care. *Gynecol Oncol Reports*. 2015 Feb;12:13-6. PMID: 26076150. PMCID: PMC4442651
89. Scott CL, **Swisher EM**, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. *J Clin Oncol*. 2015 April 20;33(12):1397-406. PMID: 25779564. PMCID: PMC4517072
90. Liao JB, Yip YY, **Swisher EM**, Agnew K, Hellstrom KE, Hellstrom KE, Hellstrom I. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: clinical correlates. *Gynecol Oncol*. 2015 June;137(3):430-5. PMID: 25866324. PMCID: PMC4447602
91. Coleman R, Sill MW, Bell-McGuinn K, Aghajanian CA, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, **Swisher EM**. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2015 June;137(3):386-91. PMID:25818403. PMCID: PMC4447602
92. Chien J, Sicotte H, Fan JB, Humphrey S, Cunningham JM, Kalli KR, Oberg AL, Hart SN, Li Y, Davila JI, Baheti S, Wang C, Dietmann S, Atkinson EJ, Asmann YW, Bell DA, Ota T, Tarabishy Y, Kuang R, Bibikova M, Cheetham RK, Grocock RJ, **Swisher EM**, Peden J, Bentley D, Kocher JP, Kaufmann SH, Hartmann LC, Shridhar V, Goode EL. TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. *Nucleic Acid Res*. 2015 Aug 18;43(14):6945-58. PMID: 25916844. PMCID: PMC4538798
93. Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Stychor S, Kiesel B, Linden HM, Thompson JA, **Swisher EM**, Chai X, Shepherd S, Giranda V, Specht JM. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. *Clin Cancer Res*. 2016 Jan 22. PMID: 26801247. PMCID: PMC4911292
94. Bernards SS, Norquist BM, Harrell MI, Agnew KJ, Lee MK, Walsh T, **Swisher EM**. Genetic characterization of early onset ovarian carcinoma. *Gynecol Oncol*. 2016 Feb;140(2):221-5. PMID: 26718727. PMCID: PMC4869974
95. **Swisher EM**, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli KR, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, Birrer MJ. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women with Ovarian Carcinoma. *JAMA Oncol*. 2016 Mar 1;2(3):370-2. PMID: 26847329. PMCID: PMC4865293
96. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, **Swisher EM**, Birrer MJ. Inherited mutations in women with ovarian carcinoma. *JAMA Oncol*. 2016 Apr 1;2(4):482-90. PMID: 26720728, PMCID: PMC4865293
97. Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR, Emond MJ, Loeb LA, **Swisher EM**, Risques RA. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. *Proc Natl Acad Sci U S A*. 2016 May 24;113(21):6005-10. PMID: 27152024. PMCID: PMC4889384
98. Wang Y, Bernhardt AJ, Cruz C, Kraus JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan

- B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, **Swisher EM**, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N. The BRCA1- $\Delta$ 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. *Cancer Res.* 2016 May 1;76(9):2778-90. PMID: 27197267. PMCID: PMC4874568
99. Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp J, **Swisher EM**, McDevett M, Kaufmann SH. Poly(ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. *Clin Cancer Res.* 2016 Aug 1;22(15):3894-902. PMID: 26979391. PMCID: PMC5041297
100. Wang Y, Kraiss JJ, Bernhardt AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, **Swisher EM**, Simpkins F, Johnson N. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. *J Clin Invest.* 2016 Aug 1;126(8):3145-57. PMID: 27454289. PMCID: PMC4966309
101. Sherman M, Drapkin R, Horowitz NS, Crum CP, Friedman S, Kwon J, Levine DA, Shih IM, Shoupe D, **Swisher EM**, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian L. Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-grade Serous Carcinoma: A Review of the Evidence. *Cancer Prev Res (Phila).* 2016 Sep;9(9):713-20. PMID: 27221539. PMCID: PMC5010984
102. Wald K, Easterling T, **Swisher EM**. Spontaneous Twin Pregnancy After Oophorectomy and Pelvic Radiation for Rectal Cancer. *Obstet Gynecol.* 2016 Oct;128(4):792-4. PMID: 27607863
103. Morse CB, Norquist BM, Harrell MI, Agnew KJ, Gray HJ, Urban RR, Garcia RL, Goff BA, **Swisher EM**. Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma. *Gynecol Oncol.* 2016 Nov;143(2):389-392. PMID: 27575909
104. AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxon KM, Kalli KR, **Swisher EM**, Kaufmann SH, Haluska P. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. *Gynecol Oncol.* 2016 Nov;143(2):379-388. PMID: 27614696. PMCID: PMC5370566
105. Stewart L, Garg R, Garcia R, **Swisher E**. Small cell ovarian carcinoma: Long term survival in juvenile case with poor prognostic features. *Gynecol Oncol Rep.* 2016 Nov 9;18:45-48. PMID: 27896308. PMCID: PMC5121138
106. Kilgore MR, McIlwain CA, Schmidt RA, Norquist BM, **Swisher EM**, Garcia RL, Rendi MH. Reflex test reminders in required cancer synoptic templates decrease order entry error: An analysis of mismatch repair immunohistochemical orders to screen for Lynch syndrome. *J Pathol Inform.* 2016 Nov 29;7:48. PMID: 27994940. PMCID: PMC5139450
107. Stover EH, Konstantinopoulos PA, Matulonis UA, **Swisher EM**. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. *Clin Cancer Res.* 2016 Dec 1;22(23):5651-5660. PMID: 27678458
108. **Swisher EM**, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-

- grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncology*. 2017 Jan;18(1):75-87. PMID: 27908594
109. Lee JM, Hays JL, Chiou VL, Annunziata CM, **Swisher EM**, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. *Oncotarget*. 2017 Mar 25. [Epub ahead of print] PMID: 28388551
  110. Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, **Swisher EM**, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. *Ann Oncol*. 2017 May 1;28(5):996-1004. PMID: 28453702. PMCID: PMC5406764
  111. Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, **Swisher EM**, Takenaka M, Bowtell DD, Sherman ME. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. *J Clin Oncol*. 2017 Jul 10;35(20):2329-2337. PMID: 28398847. PMCID: PMC5501360
  112. Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, **Swisher EM**, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. *J Clin Oncol*. 2017 Jul 1;35(19):2193-2202. PMID: 28471727. PMCID: PMC5493052
  113. Randall LM, Pothuri B, **Swisher EM**, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. *Gynecol Oncol*. 2017 Aug;146(2):217-224. PMID: 28596016
  114. Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, **Swisher EM**, Lin KK, Scott CL; AOCs Study Group. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. *Cancer Discov*. 2017 Sep;7(9):984-998. PMID: 28588062
  115. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, **Swisher EM**, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. *Gynecol Oncol*. 2017 Nov;147(2):267-275. PMID: 28882436
  116. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, **Swisher EM**, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA, ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after

- response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017 Oct 28;390(10106): 1949-1961. PMID: 28916367. PMCID: PMC5901715
117. Wahner Hendrickson AE, Kaufmann SH, **Swisher EM**. Doubling Down on BRCA-Mutated Cancer. *Trends Cancer*. 2017 Nov;3(11):743-744. PMID:29120748. PMCID: PMC5901715
  118. Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, **Swisher EM**, Poirer GG, Satele D, Allred JB, Lensing JL, Chen A, Ji JJ, Zhang Y, Erlichman C, Haluska P, Kaufmann SH. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. *Clin Cancer Res*. 2018 Feb 15;24(4):744-752. PMID: 29138343. PMCID: PMC7580251
  119. Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, **Swisher EM**. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. *Gynecol Oncol*. 2018 Feb;148(2):281-285. PMID: 29233532
  120. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes FJ, Mannel RS, Glaser G, Bailey C, Rubin SC, Soper JT, Lankes HA, Ramirez NC, King MC, Birrer MJ, **Swisher EM**. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. *Clin Cancer Res*. 2018 Feb 15;24(4):777-783. PMID: 29191972. PMCID: PMC5815909
  121. Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, **Swisher EM**, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. *Lancet Oncol*. 2018 Feb;19 (2):207-215. PMID:29361470. PMCID: PMC7366122
  122. Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Raney M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, **Swisher EM**, Stoyanov S, Yusa K, Ashworth A, Lord CJ. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. *Nat Commun*. 2018 May 10;9(1):1849. PMID:29748565 PMCID:PMC5945626
  123. Werner TL, Sachdev J, **Swisher EM**, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR. Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. *Cancer Med*. 2018 Jun;7(6):2360-2369. PMID: 29733524 PMCID: PMC6010916
  124. Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Kraiss JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, **Swisher EM**, Dobrovic A, Wakefield MJ, Scott CL. Methylation of all *BRCA1* copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. *Nat Commun*. 2018 Sep 28;9(1):3970. PMID: 30266954 PMCID:PMC6162272
  125. Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, **Swisher EM**, Konstantinopoulos PA, Chowdhury D. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. *Cell Rep*. 2018 Apr 3;23(1):100-111. PMID:29617652 PMCID: PMC5908239
  126. Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, **Swisher EM**, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Prediction of

- DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. *Cancer Discov.* 2018 Nov;8(11):1404-1421. PMID:30213835. PMCID: PMC6365285
127. Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, **Swisher EM**. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to PARP inhibition in high-grade ovarian carcinoma. *Cancer Discov.* 2019 Feb;9(2):210-219. PMID:30425037
  128. Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, **Swisher EM**. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. *Gynecol Oncol.* 2019 Apr;153(1):192-200. PMID:30661763
  129. Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, **Swisher EM**, Kaufmann SH. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. *Gynecol Oncol.* 2019 Apr;153(1):127-134. PMID:30686551. PMCID: PMC6430710
  130. Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, Pennington KP, Garcia RL, Liao JB, **Swisher EM**. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. *Gynecol Oncol.* 2019 May;153(2):217-222. PMID:30803719. PMCID: PMC6486839
  131. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, **Swisher EM**, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and  $\alpha$ -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. *Lancet Oncol.* 2019 Apr;20(4):570-580. PMID: 30880072 PMCID: PMC6557782
  132. Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, **Swisher EM**, Kilgore MR. An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions. *Int J Gynecol Pathol.* 2020 May;39(3):261-269. PMID: 31033800; PMCID: PMC6813866
  133. Eurich KE, **Swisher E**, Toukatly M, Koch L, Wu ES. A case of metastatic dysgerminoma treated with two cycles neoadjuvant chemotherapy followed by fertility-sparing minimally invasive surgery. *Gynecol Oncol Rep.* 2019 Apr 6;28:124-127. PMID:31024985 PMCID: PMC6476800
  134. Hellstrom I, Yip YY, Darvas M, **Swisher E**, Hellstrom KE. Ovarian carcinomas express HE4 epitopes independently of each other. *Cancer Treat Res Commun.* 2019 May 24;21:100152. Epub 2019 May 24. PMID:31226514
  135. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, **Swisher EM**, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. *JAMA Oncol.* 2019 Jun 13;5(8):1141-9. PMID: 31194228; PMCID: PMC6567832.
  136. Rayes N, Bowen DJ, Coffin T, Nebgen D, Peterson C, Munsell MF, Gavin K, Lechner R, Crase J, Polinsky D, Romero I, Blank SV, Levine DA, Norquist BM, **Swisher EM**, Lu KH. MAGENTA (Making

- Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing. *BMC Cancer*. 2019 Jul 2;19(1):648. PMID:31266460. PMCID: PMC6604336
137. Jorge S, **Swisher EM**, Norquist BM, Pennington KP, Gray HJ, Urban RR, Garcia RL, Doll KM. Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. *Gynecol Oncol Rep*. 2019 Aug 9;29:113-117. PMID: 31467964; PMCID: PMC6710556
  138. Tewari KS, Burger RA, Enserro D, Norquist BM, **Swisher EM**, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. *J Clin Oncol*. 2019 Sep 10;37(26):2317-2328 PMID:31216226. PMCID: PMC6879307
  139. Norquist BM, **Swisher EM**, Yung RL. Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy? *JNCI Cancer Spectr*. 2019 Oct 4;4(1):pkz076. PMID: 32337493; PMCID: PMC7050155.
  140. Coleman RL, Fleming GF, Brady MF, **Swisher EM**, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. *N Engl J Med*. 2019 Dec 19;381(25):2403-2415. PMID:31562800. PMCID: PMC6941439
  141. Jorge S, McFaddin AS, Doll KM, Pennington KP, Norquist BM, Bennett RL, Pritchard CC, **Swisher EM**. \*Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. *Gynecol Oncol*. 2020 Mar;156(3):517-522. PMID:31883735  
\*Editor's Choice
  142. Casadei S, Gulsuner S, Shirts BH, Mandell JB, Kortbawi HM, Norquist BS, **Swisher EM**, Lee MK, Goldberg Y, O'Connor R, Tan Z, Pritchard CC, King MC, Walsh T. Characterization of splice-altering mutations in inherited predisposition to cancer. *Proc Natl Acad Sci U S A*. 2019 Dec 16;116(52):26798–807. Epub ahead of print. PMID: 31843900. PMCID: PMC6936554
  143. Wang Y, Bernhardt AJ, Nacson J, Kraus JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, **Swisher EM**, Serra V, Peri S, Johnson N. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. *Nat Commun*. 2019 Dec 11;10(1):5661. PMID:31827092. PMCID: PMC6906494
  144. Drew Y, Kristeleit RS, Oaknin A, Ray-Coquard I, Haris NM, **Swisher EM**. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. *Oncologist*. 2020 Jan;25(1):e109-e119. PMID: 31575788. PMCID: PMC6964123
  145. Moyer CL, Ivanovich J, Gillespie JL, Doberstein R, Radke MR, Richardson ME, Kaufmann SH, **Swisher EM**, Goodfellow PJ. Rare BRIP1 missense alleles confer risk for ovarian and breast cancer. *Cancer Res*. 2020 Feb 15;80(4):857-867. CAN-19-1991. PMID: 31822495. PMCID: PMC8722358

146. Krimmel-Morrison JD, Ghezelayagh TS, Lian S, Zhang Y, Fredrickson J, Nachmanson D, Baker KT, Radke MR, Hun E, Norquist BM, Emond MJ, **Swisher EM**, Risques RA. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. *Gynecol Oncol*. 2020 Feb;156(2):407-414. PMID: 31839337. PMCID: PMC7018621
147. Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardt AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, **Swisher EM**, Mischel PS, Johnson N, Bitler BG. Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations. *Mol Cancer Ther*. 2020 Feb;19(2):602-613. PMID:31575654. PMCID: PMC7007853
148. Ghezelayagh TS, Stewart LE, Norquist BM, Bowen DJ, Yu V, Agnew KJ, Pennington KP, **Swisher EM**. Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention. *Fam Cancer*. 2020 Apr;19(2):143-151. PMID: 32096072
149. Rush SK, **Swisher EM**, Garcia RL, Pennington KP, Agnew KJ, Kilgore MR, Norquist BM. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. *Gynecol Oncol*. 2020 May;157(2):514-520. PMID: 32199636
150. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, **Swisher EM**, D'Andrea AD, Konstantinopoulos PA. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. *Nat Commun*. 2020 Mar 19;11(1):1459. Erratum in: *Nat Commun*. 2020 May 18;11(1):2543. PMID: 32193378. PMCID: PMC7081234
151. Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, **Swisher EM**, Cameron T, Maloney L, Goble S, Coleman RL. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2020 May;21(5):710-722. PMID: 32359490. PMCID: PMC8210534
152. Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehoul J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, **Swisher EM**, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. *J Natl Cancer Inst*. 2020 Dec 14;112(12):1190-120. PMID: 32413141. PMCID: PMC7735770
153. Lampert EJ, Zimmer AS, Padgett MR, Cimino-Mathews A, Nair JR, Liu Y, **Swisher EM**, Hodge JW, Nixon AB, Nichols E, Bagheri M, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study. *Clin Cancer Res*. 2020 May 12:clincanres.0056.2020. Epub 2020 May 12. PMID: 32398324. PMCID: PMC7442720
154. Hillman RT, Cardnell R, Fujimoto J, Lee WC, Zhang J, Byers LA, Ramalingam P, Leitao M, **Swisher E**, Futreal PA, Frumovitz M. Comparative genomics of high grade neuroendocrine carcinoma of the cervix. *PLoS One*. 2020 Jun 16;15(6):e0234505. eCollection 2020. PMID: 32544169. PMCID:PMC7297329

155. Weiss AS, **Swisher E**, Pennington KP, Radke M, Khasnavis N, Garcia RL, Kilgore MR, Lee MK, Norquist BM. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years. *Gynecol Oncol* 2020 Jul 21;S0090-8258(20)32335-0. PMID: 32709535
156. Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, **Swisher EM**, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma *Gynecol Oncol* 2020 Jul 31;S0090-8258(20)31130-6. PMID: 32861537. PMCID: PMC8450972
157. Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, **Swisher EM**, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma *J Clin Oncol* 2020 Aug 24;JCO1903107. PMID: 32840418. PMCID: PMC7571791
158. Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, **Swisher EM**, Yates LR. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer *Ann Oncol*. 2020 Sep 28;S0923-7534(20)42164-7. PMID: 33004253
159. Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, **Swisher EM**, Grandori C. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer *EBioMedicine*. 2020 Oct;60:102988. PMID: 32927276. PMCID: PMC7494677
160. Zhang Y, Kohn BF, Yang M, Nachmanson D, Soong TR, Lee IH, Tao Y, Hans Clevers H, **Swisher EM**, Brentnall TA, Loeb LA, Kennedy SR, Salk JJ, Naxerova K, Risques RA PolyG-DS: An Ultra-Sensitive Polyguanine Tract Profiling Method to Detect Clonal Expansions and Trace Cell Lineage. *Proc National Acad of Science* 2020 (in press)
161. Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, **Swisher EM**, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. *J Natl Cancer Inst*. 2020 Dec 14;112(12):1190-1203. PMID: 32413141. PMCID: PMC7735770
162. Bowen DJ, Wang C, Cole AM, Norquist BM, Knerr S, Devine B, Shirts B, Cain K, Harris HM, Haile HG, **Swisher EM**. Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care. *Contemp Clin Trials*. 2020 Dec 26;101:106257. Epub 2020 Dec 26. PMID: 33373667. PMCID: PMC8075171
163. Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, **Swisher EM**. Characterizing TP53 mutations in ovarian

- carcinomas with and without concurrent BRCA1 or BRCA2 mutations. *Gynecol Oncol*. 2021 160(3):786-792. PMID: 33375991. PMCID: PMC8491988
164. Shigeta S, Lui GYL, Shaw R, Moser R, Gurley KE, Durenberger G, Rosati R, Diaz RL, Ince TA, **Swisher EM**, Grandori C, Kemp CJ. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. *Mol Cancer Ther*. 2021 Jan 28;. Epub 2021 Jan 28. PMID: 33509905. PMCID: PMC8026742
165. Sullivan MR, Prakash R, Rawal Y, Wang W, Sung P, Radke MR, Kaufmann SH, **Swisher EM**, Bernstein KA, Jasin M. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. *Cold Spring Harb Mol Case Stud*. 2021 Apr 8;7(2):a006083. PMID: 33832919. PMCID: PMC8040731
166. **Swisher EM**, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafir A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). *Nat Commun*. 2021 May 3;12(1):2487. PMID: 33941784. PMCID: PMC8093258
167. Chang AE, Radke MR, Zhen DB, Baker KK, Coveler AL, Wong KM, Pillarisetty VG, Reddi D, Redman MW, **Swisher E**, Chiorean EG. DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. *Pancreas*. 2021 May-Jun 01;50(5):e50-e52. PMID: 34106577. PMCID: PMC8585585
168. Aghajanian C, Bookman MA, Fleming GF, **Swisher EM**, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. *Gynecol Oncol*. 2021 Jun 7:S0090-8258(21)00437-6. Epub 2021 Jun 8. PMID: 34112513
169. Mauro LJ, Seibel MI, Diep CH, Spartz A, Perez Kerkvliet C, Singhal H, **Swisher EM**, Schwartz LE, Drapkin R, Saini S, Sesay F, Litovchick L, Lange CA. Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models. *J Clin Endocrinol Metab*. 2021 Jun 16;106(7):1929-1955. PMID: 33755733. PMCID: PMC8499172
170. Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, **Swisher EM**, Xiao JJ. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. *Gynecol Oncol*. 2021 Jun;161(3):668-675. Epub 2021 Mar 19. PMID: 33752918
171. Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, **Swisher EM**, Cameron T, Goble S, Coleman RL, Ledermann JA. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. *Int J Gynecol Cancer*. 2021 Jul;31(7):949-958. Epub 2021 Jun 8. PMID: 34103386

172. Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, **Swisher EM**, Li H, Weroha SJ, Kaufmann SH. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. *NAR Cancer*. 2021 Jul 9;3(3):zcab028. PMID: 34316715. PMCID: PMC8271218
173. Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, Fahr N, Desbuisson M, Grimm A, Zhang H, Chong C, Dagher J, Chee S, Tsianou T, Dorier J, Stevenson BJ, Iseli C, Ronet C, Bobisse S, Genolet R, Walton J, Bassani-Sternberg M, Kandalaf LE, Ren B, McNeish I, **Swisher E**, Harari A, Delorenzi M, Ciriello G, Irving M, Rusakiewicz S, Foukas PG, Martinon F, Dangaj Laniti D, Coukos G. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. *Cell Rep*. 2021 Jul 20;36(3):109412. PMID: 34289354. PMCID: PMC8371260
174. Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafir A, Chai ZQ, Eftekhariyan Ghamsari MR, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Cancer Study AO, DeFazio A, Bowtell DDL, **Swisher EM**, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma. *Cancer Res*. 2021 15;81(18):4709-4722. PMID: 34321239
175. Wethington SL, Wahner-Hendrickson AE, **Swisher EM**, Kaufmann SH, Karlan BY, Fader AN, Dowdy SC. PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine. *Gynecol Oncol*. 2021 Aug 11: S0090-8258(21)00647-8. Epub 2021 Aug 12 PMID: 34391577
176. Zhang Y, Kohn BF, Yang M, Nachmanson D, Soong TR, Lee IH, Tao Y, Clevers H, **Swisher EM**, Brentnall TA, Loeb LA, Kennedy SR, Salk JJ, Naxerova K, Risques RA. PolyG-DS. An ultrasensitive polyguanine tract-profiling method to detect clonal expansions and trace cell lineage. *Proc National Acad Sciences* Aug 3;118(31):e2023373118. PMID: 34330826. PMCID: PMC8346827
177. Somasegar S, Weiss AS, Norquist BM, Khasnavis N, Radke M, Manhardt E, Pennil C, Pennington KP, Eckert MA, Chryplewicz A, Lengyel E, **Swisher EM**. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas *Gynecol Oncol* 2021 Aug 24;S0090-8258(21)01315-9. Epub 2021 Aug 24. PMID: 34452747
178. Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amedeo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, Garcia-Donas J, **Swisher EM**, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. *Cancer Med*. 2021 Sep 21. Epub 2021 Sep 21. PMID: 34549539. PMCID: PMC8525125
179. Chiorean EG, Guthrie KA, Philip PA, **Swisher EM**, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS.

Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. *Clin Cancer Res.* 2021 Sep 27;clincanres.1789.2021. Online ahead of print PMID: 34580114. PMCID: PMC8639715

180. **Swisher EM**, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. *Gynecol Oncol* 2021 Sep 30;S0090-8258(21)01329-9. Epub 2021 Sep 30. PMID: 34602290
181. Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Aghajanian C, Lorusso D, Colombo N, Dean A, Weberpals JI, Severson E, Vo LT, Goble S, Maloney L, Harding T, Kaufmann SH, Ledermann JA, Coleman RL, McNeish IA, Lin KK, **Swisher EM**. Preexisting TP53-mutated clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer patients treated with rucaparib. *JAMA Oncology* 2021 1;7(12):1772-1781. PMID: 34647981. PMCID: PMC8517887
182. Csizmar CM, Saliba AN, **Swisher EM**, Kaufmann SH. PARP inhibitors and myeloid neoplasms: a double-edged sword. *Cancers (Basel)*. 2021 Dec 20;13(24):6385. doi: 10.3390/cancers13246385.PMID: 34945003. PMCID: PMC8699275
183. Aghajanian C, **Swisher EM**, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. *Gynecol Oncol.* 2021 Dec 17:S0090-8258(21)01638-3. Epub 2021 Dec 18. PMID: 34930617
184. **Swisher EM**, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. *Gynecol Oncol.* 2021 Dec 11:S0090-8258(21)01630-9. Epub 2021 Dec 11. PMID: 34906376 (Editor's choice February, 2022 issue)
185. Steenbeek MP, van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, Cun HT, Lu KH, van Beekhuizen HJ, Minig L, Gaarenstroom KN, Nobbenhuis M, Krajc M, Rudaitis V, Norquist BM, **Swisher EM**, Mourits MJE, Massuger LFAG, Hoogerbrugge N, Hermens RPMG, Int'Hout J, de Hullu JA. Risk of peritoneal carcinomatosis after risk-reducing Salpingo-Oophorectomy: a systematic review and individual patient data meta-analysis. *J Clin Oncol.* 2022 Jun 10;40(17):1879-1891. Epub 2022 Mar 18. PMID: 35302882
186. Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, **Swisher EM**, Matulonis UA, Wulf GM, Mayer EL. Phase 1b clinical trial with Alpelisib plus Olaparib for patients with advanced triple-negative breast cancer. *Clin Cancer Res.* 2022 Apr 14;28(8):1493-1499. CCR-21-3045. PMID: 35149538. PMCID: PMC9066379

187. Dusic EJ, Bowen DJ, Bennett R, Cain KC, Theorin T, Velasquez M, **Swisher E**, Brant JM, Shirts B, Wang C. Socioeconomic status and interest in genetic testing in a US-based sample. *Healthcare (Basel)*. 2022 May 10;10(5):880. PMID: 35628017. PMCID: PMC9141316
188. Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaard B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, **Swisher EM**, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN- 8282 study team. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. *Cancer Chemother Pharmacol*. 2022 May;89(5):721-735. PMID: 35435472. PMCID: PMC9116722
189. Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, **Swisher EM**, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib with or without Cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial. *J Clin Oncol*. 2022 Mar 15;JCO2102011. Epub ahead of print. PMID: 35290101
190. Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, **Swisher EM**, Liu ET. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. *Sci Transl Med*. 2022 Jul 6;14(652) PMID: 35857626
191. You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, **Swisher EM**. CA-125 KELIM as a potential complementary tool for predicting Veliparib benefit: an exploratory analysis from the VELIA/GOG-3005 study. *J Clin Oncol*. 2022 Jul 22;JCO2200430. Epub ahead of print. PMID: 35867965
192. Prakash R, Rawal Y, Sullivan MR, Grundy MK, Bret H, Mihalevic MJ, Rein HL, Baird JM, Darrah K, Zhang F, Wang R, Traina TA, Radke MR, Kaufmann SH, **Swisher EM**, Guéris R, Modesti M, Sung P, Jasin M, Bernstein KA. Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants. *Proc Natl Acad Sci U S A*. 2022 Sep 20;119(38):e2202727119. Epub 2022 Sep 13. PMID: 36099300; PMCID: PMC9499524
193. Coffin T, Bowen D, Lu K, **Swisher EM**, Rayes N, Norquist B, Blank SV, Levine DA, Bakkum-Gamez JN, Fleming GF, I Olopade O, Romero I, D'Andrea A, Nebgen DR, Peterson C, Munsell MF, Gavin K, Crase J, Polinsky D, Lechner R. Using social media to facilitate communication about women's testing: tool validation study. *JMIR Form Res*. 2022 Sep 26;6(9):e35035. PMID: 36155347; PMCID: PMC9555323
194. Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, **Swisher EM**, Kohn EC, Zamarin D. State of the biomarker science in ovarian cancer: a National Cancer Institute Clinical Trials Planning Meeting Report. *JCO Precis Oncol*. 2022 Oct;6:e2200355. PMID: 36240472
195. You B, Purdy C, Copeland LJ, **Swisher EM**, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. Identification of patients with ovarian cancer

- experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study. *J Clin Oncol*. 2022 Oct 17. PMID: 36252167
196. Coffin T, Bowen D, **Swisher E**, Lu K, Rayes N, Norquist B, Blank S, Levine D, Bakkum-Gamez J, Fleming G, Olopade O, D'Andrea A, Nebgen D, Peterson C, Munsell M, Gavin K, Lechner R, Crase J, Polinsky D, Romero I. An accessible communication system for population-based genetic testing: development and usability study. *JMIR Form Res*. 2022 Oct 17;6(10). PMID: 36251350
  197. Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bublely G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, **Swisher EM**, Petrylak DP. Randomized trial of Olaparib with or without Cediranib for metastatic castration-resistant prostate cancer: the results from National Cancer Institute 9984. *J Clin Oncol*. 2022 Oct 18. PMID: 36256912
  198. O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JL, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, **Swisher EM**, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. *Gynecol Oncol*. 2022 Dec;167(3):404-413. Epub 2022 Oct 20. PMID: 36273926
  199. Ghezelayagh TS, Kohn BF, Fredrickson J, Manhardt E, Radke MR, Katz R, Gray HJ, Urban RR, Pennington KP, Liao JB, Doll KM, Simons EJ, Burzawa JK, Goff BA, Speiser P, **Swisher EM**, Norquist BM, Risques RA. Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer. *Cancer Res Commun*. 2022 Oct;2(10):1282-1292. Epub 2022 Oct 27. PMID: 36311816; PMCID: PMC9615025
  200. Dusic EJ, Theorin T, Wang C, **Swisher EM**, Bowen DJ; EDGE Study Team. Barriers, interventions, and recommendations: Improving the genetic testing landscape. *Front Digit Health*. 2022 Nov 1;4:961128. PMID: 36386046; PMCID: PMC9665160
  201. Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, **Swisher EM**, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2023 Jan 6:S1470-2045(22)00739-2. PMID: 36623515
  202. Colombaro O, **Swisher EM**, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, Lin KK, Maloney L, Freyer G, You B. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10. *EBioMedicine*. 2023 Mar;89:104477. Epub 2023 Feb 16. PMID: 36801617; PMCID: PMC9972491
  203. Jorge S, Masshoor S, Gray HJ, **Swisher EM**, Doll KM. Participation of patients with limited English proficiency in gynecologic oncology clinical trials. *J Natl Compr Canc Netw*. 2023 Jan;21(1):27-32.e2. PMID: 36634612

204. Oluloro A, Temkin SM, Jackson J, **Swisher EM**, Sage L, Doll K. What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women. *Gynecol Oncol*. 2023 May;172:29-35. Epub 2023 Mar 15. PMID: 36931101; PMCID: PMC10192016
205. Nestic K, Krais JJ, Vandenberg CJ, Wang Y, Patel P, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, **Swisher EM**, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. *medRxiv [Preprint]*. 2023 Mar 21:2023.03.20.23287465. doi: 10.1101/2023.03.20.23287465. PMID: 36993400; PMCID: PMC10055590
206. Krumm N, Khasnavis NS, Radke M, Banda K, Davies HR, Pennil C, McLean K, Paulson VA, Konnick EQ, Johnson WC, Huff G, Nik-Zainal S, **Swisher EM**, Lockwood CM, Salipante SJ. Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays. *JCO Precis Oncol*. 2023 May;7:e2200720. PMID: 37196218
207. Gray HJ, Chatterjee P, Rosati R, Appleyard LR, Durenberger GJ, Diaz RL, Swan HA, Peretti D, Pollastro M, Ainge T, Kapeli K, Pereira S, Margossian AL, Banda K, Goff BA, **Swisher EM**, Bernard B, Kemp CJ, Grandori C. Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing. *NPJ Precis Oncol*. 2023 May 18;7(1):45. PMID: 37202426; PMCID: PMC10195827
208. Steenbeek MP, van Bommel MHD, intHout J, Peterson CB, Simons M, Roes KCB, Kets M, Norquist BM, **Swisher EM**, Hermens RPMG; TUBA-WISP II consortium; Lu KH, de Hullu JA. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. *Int J Gynecol Cancer*. 2023 May 25:ijgc-2023-004377. Epub ahead of print. PMID: 37045546
209. Gupta N, Huang TT, Nair JR, An D, Zurcher G, Lampert EJ, McCoy A, Cimino-Mathews A, **Swisher EM**, Radke MR, Lockwood CM, Reichel JB, Chiang CY, Wilson KM, Cheng KC, Nousome D, Lee JM. *BLM* overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant *BRCA*-mutant ovarian cancer. *Sci Transl Med*. 2023 Jun 21;15(701). PMID: 37343085
210. Wang JY, Ma KK, Reiter DJ, Torvie A, **Swisher EM**. Sertoli-Leydig cell tumor associated with a germline *DICER1* pathogenic variant diagnosed during pregnancy: Considerations for treatment, surveillance, and prevention. *Gynecol Oncol Rep*. 2023 Jun 2;48:101215. PMID: 37334322
211. **Swisher EM**, Rayes N, Bowen D, Peterson CB, Norquist BM, Coffin T, Gavin K, Polinsky D, Crase J, Bakkim-Gamez JN, Blank SV, Munsell MF, Nebgen D, Fleming GF, Olopade OI, Law S, Zhou A, Levine DA, D'Andrea A, Lu KH. MAGENTA: a randomized, four-arm non-inferiority trial of remotely delivered cancer genetic testing. *JAMA Oncology* 2023, Sep 14. PMID: 37707822
212. *BLM* overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant *BRCA*-mutant ovarian cancer. Gupta N, Huang TT, Nair JR, An D, Zurcher G, Lampert EJ, McCoy A, Cimino-Mathews A, **Swisher EM**, Radke MR, Lockwood CM, Reichel JB, Chiang CY, Wilson KM, Cheng KC, Nousome D, Lee JM. *Sci Transl Med*. 2023 Jun 21;15(701):eadd7872. Epub 2023 Jun 21. PMID: 37343085
213. Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. Duska LR, Zamarin D,

- Hamilton E, Oza A, Fleming G, Spira A, Yeku OO, Richardson DL, Walling J, Inokuchi K, Matusow B, Bollag G, **Swisher EM**. JCO Precis Oncol. 2023 Sep;7:e2300235. PMID: 37797273
214. Rodriguez IV, Strickland S, Wells D, Manhardt E, Konnick EQ, Garcia R, **Swisher E**, Kilgore M, Norquist B. Adoption of Universal Testing in Endometrial Cancers for Microsatellite Instability Using Next-Generation Sequencing. JCO Precis Oncol. 2023 Sep;7:e2300033. PMID: 37856764
215. Liu ZS, Sinha S, Bannister M, Song A, Arriaga-Gomez E, McKeeken AJ, Bonner EA, Hanson BK, Sarchi M, Takashima K, Zong D, Corral VM, Nguyen E, Yoo J, Chiraphappaiboon W, Leibson C, McMahon MC, Rai S, **Swisher EM**, Sachs Z, Chatla S, Stirewalt DL, Deeg HJ, Skorski T, Papapetrou EP, Walter MJ, Graubert TA, Doulatov S, Lee SC, Nguyen HD. R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts. Cancer Res. 2023 Nov 15. Epub ahead of print. PMID: 37967363
216. Ho GY, Vandenberg CJ, Lim R, Christie EL, Garsed DW, Lieschke E, Nesic K, Kondrashova O, Ratnayake G, Radke M, Penington JS, Carmagnac A, Heong V, Kyran EL, Zhang F, Traficante N; Australian Ovarian Cancer Study; Huang R, Dobrovic A, **Swisher EM**, McNally O, Kee D, Wakefield MJ, Papenfuss AT, Bowtell DDL, Barker HE, Scott CL. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models. Ther Adv Med Oncol. 2023 Nov 22;15:17588359231208674. PMID: 38028140; PMCID: PMC10666702
217. Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, Borowsky M, Moroney J, Hendrickson AW, Backes F, **Swisher E**, Powell M, MacKay H. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15;130(8):1234-1245. PMID: 38127487
218. Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, **Swisher EM**, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. Br J Cancer. 2024 Feb;130(3):476-48. PMID: 38135713, PMCID: PMC10844282
219. Geissler F, Nesic K, Kondrashova O, Dobrovic A, **Swisher EM**, Scott CL, J Wakefield M. The role of aberrant DNA methylation in cancer initiation and clinical impacts. Ther Adv Med Oncol. 2024 Jan 28;16:17588359231220511. PMID: 38293277; PMCID: PMC10826407
220. Yu B, Liu C, Proll SC, Manhardt E, Liang S, Srinivasan S, **Swisher E**, Fredricks DN. Identification of fallopian tube microbiota and its association with ovarian cancer. Elife. 2024 Mar 7;12:RP89830. PMID: 38451065; PMCID: PMC10942644
221. Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Noursome D, Radke MR, **Swisher EM**, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel JB, Lee JM. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nat Commun. 2024 Mar 30;15(1):2805. PMID: 38555285; PMCID: PMC10981752
222. Manchanda R, Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, Oxley S, Sideris M, Fierheller CT, Morgan RD, Chandrasekaran D, Rust K, Spiliopoulou P, Miller RE, Crusz SM, Lockley M, Singh N, Faruqi A, Casey L, Brockbank E, Phadnis S, Mills-Baldock T, El-Khouly F, Jenkins LA, Wallace A,

- Ahmed M, Kumar A, **Swisher EM**, Gourley C, Norquist BM, Evans DG, Legood R. Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. *J Natl Compr Canc Netw*. 2024 Apr 18;22(2D):e237331. PMID: 38866043
223. Liu JF, Xiong N, Wenham RM, Wahner-Hendrickson A, Armstrong DK, Chan N, O'Malley DM, Lee JM, Penson RT, Cristea MC, Abbruzzese JL, Matsuo K, Olawaiye AB, Barry WT, Cheng SC, Polak M, **Swisher EM**, Shapiro GI, Kohn EC, Ivy SP, Matulonis UA. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib. *Gynecol Oncol*. 2024 May 16;187:105-112. Epub ahead of print. PMID: 38759516
224. Ghezelayagh TS, Kohn BF, Fredrickson J, Krimmel-Morrison JD, Latorre-Esteves E, Tee XR, Radke MR, Manhardt E, Norquist BM, Katz R, **Swisher EM**, Risques RA. TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations. *Oncogene*. 2024 Jul;43(31):2421-2430. Epub 2024 Jun 25. PMID: 38918516; PMCID: PMC11370867
225. Nesic K, Krais JJ, Wang Y, Vandenberg CJ, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Betsch R, Xu L, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, McNeish I, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, **Swisher EM**, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. *Mol Cancer*. 2024 Aug 5;23(1):158. PMID: 39103848; PMCID: PMC11299415
226. Tee XR, Hazard E, Latorre-Esteves E, Kohn BF, Ghezelayagh TS, Fredrickson JU, Coombes C, Radke MR, Manhardt E, Katz R, Soong TR, **Swisher EM**, Norquist BM, Risques RA. Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations. *Gynecol Oncol*. 2024 Aug 10;190:18-27. Epub ahead of print. PMID: 39128337
227. Venkatachalam A, Correia C, Peterson KL, Hou X, Schneider PA, Strathman AR, Flatten KS, Sine CC, Balczewski EA, McGehee CD, Larson MC, Duffield LN, Meng XW, Vincelette ND, Ding H, Oberg AL, Couch FJ, **Swisher EM**, Li H, Weroha SJ, Kaufmann SH. Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors. *Mol Cancer*. 2024 Oct 7;23(1):224. PMID: 39375715; PMCID: PMC11457406
228. Conner S, Theorin T, Dusic E, Beers F, Knerr S, Norquist B, Shirts BH, Bowen D, **Swisher EM**, Wang C. Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: A mixed methods study *Genet Med*. 2024 Oct 28:101307. Online ahead of print.
229. Oluloro A, **Swisher EM**, Gray HJ, Goff B, Doll KM. Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access. *J Natl Cancer Inst* 2024 Dec 19:djae338. Online ahead of print. PMID: 39700440
230. **Swisher EM**, Harris HM, Knerr S, Theorin TN, Norquist BM, Brant J, Shirts BH, Beers F, Cameron D, Dusic EJ, Riemann LA, Devine B, Raff ML, Kadel R, Cabral HJ, Wang C. Strategies to Assess risk for hereditary cancer in primary care clinics: a cluster randomized clinical trial. *JAMA Netw Open*. 2025 Mar 3;8(3):e250185. PMID: 40053353; PMCID: PMC11889468

231. Nesic K, Rybinski K, Ratnayake G, Ho GY, Lim R, Radke M, Neagle C, **Swisher EM**, Wakefield MJ, Barker HE, Furuuchi K, Scott CL, Vandenberg CJ. Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models. *Clin Transl Med*. 2025 Mar;15(3):e70274. PMID: 40074693; PMCID: PMC11903193
232. Rios-Doria E, Parker EU, Kohn BF, Pike M, Coombes C, Latorre-Esteves E, Reiter DJ, Fredrickson J, Katz R, **Swisher EM**, Doll KM, Risques RA. TP53 somatic evolution in the normal endometrium of Black and White individuals. *Gynecol Oncol*. 2025 Apr 17;197:1-10. doi: 10.1016/j.ygyno.2025.04.002. Online ahead of print. PMID: 40250028
233. Hurley RM, Wagner JM, Kanakkanthara A, Venkatachalam A, Deisinger AM, Correia C, Schneider PA, Peterson KL, Macon EP, Heinzen EP, Sanjiv K, Hou X, Becker MA, Maurer MJ, Larson MC, **Swisher EM**, Li H, Oberg AL, Weroha SJ, Berglund UW, Helleday T, Kaufmann SH, Hendrickson AEW. Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity. *Exp Hematol Oncol*. 2025 Jun 23;14(1):88. doi: 10.1186/s40164-025-00681-0. PMID: 40551177; PMCID: PMC12183885
234. Coleman RL, Fleming GF, Brady MF, **Swisher EM**, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Leath CA 3rd, Cella D, Sun Z, Patel S, Tang Z, Ratajczak CK, Aghajanian C, Bookman MA. Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results. *Eur J Cancer*. 2025 Jun 17;225:115587. doi: 10.1016/j.ejca.2025.115587. Online ahead of print. PMID: 40561681
235. Gee-Rodriguez K, Indorf A, **Swisher EM**, Bialick K, Banda K. Human epidermal growth factor receptor 2 targeted agents in gynecologic cancers: an updated review. *Int J Gynecol Cancer*. 2025 May 23:101948. doi: 10.1016/j.ijgc.2025.101948. Online ahead of print. PMID: 40541542
236. Gootzen TA, Steenbeek MP, van Gelder MMHJ, van Bommel MHD, Timmer-Bonte JNH, Kets CM, Wilke RN, **Swisher EM**, Norquist BM, Lu KH; TUBA-WISP II consortium; Hermens RPMG, de Hullu JA. Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II study. *Am J Obstet Gynecol*. 2025 Jun 16:S0002-9378(25)00400-4. doi: 10.1016/j.ajog.2025.06.024. Online ahead of print. PMID: 40532962
237. Khan MH, Ibanez KR, Bowen C, Donohue D, Oluloro A, **Swisher EM**, Lee JM. Impact of global enrollment on race, ethnicity, and age representation in pivotal gynecologic cancer trials leading to US Food and Drug Administration Drug Approvals. *JCO Glob Oncol*. 2025 May;11:e2400636. doi: 10.1200/GO-24-00636. Epub 2025 May 29. PMID: 40440574
238. Nesic K, Parker P, **Swisher EM**, Kraiss JJ. DNA repair and the contribution to chemotherapy resistance. *Genome Med*. 2025 May 26;17(1):62. doi: 10.1186/s13073-025-01488-8. PMID: 40420317; PMCID: PMC12107761
239. Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, Garcia-Donas J, **Swisher EM**, Lebreton C, Konecny GE, McNeish IA, Scott CL, Maloney L, Goble S, Lin KK, Coleman RL. Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. *Eur J Cancer*. 2025 Jul 25;225:115584. doi: 10.1016/j.ejca.2025.115584. Epub 2025 Jun 17. PMID: 40580808

240. Rein HL, Rawal Y, Palovcak-Lightbourn AL, Ganesan GS, Parker PS, Russell R, Darrah KE, Afsar M, Sullivan MR, Hengel SR, Radke MR, Opresko PL, Yanowitz JL, Greene EC, Lee JM, Domchek SM, **Swisher EM**, Olsen SK, Sung P, Bernstein KA. Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions. *Nat Commun*. 2025 Jul 16;16(1):6539. doi: 10.1038/s41467-025-61283-2. PMID: 40670332; PMCID: PMC12267511
241. Alson JG, Doll KM, Hempstead BH, Barr L, Lavallee DC, Sage L, Moore A, Ramsey SD, Wolff EM, Comstock BA, Monsell SE, Katz R, Gamble CR, Beavis AL, Watat M; SISTER Study Consortium. Advancing equity in cancer research through principled partnership: stakeholder engagement practices in The Social Interventions for Support during Treatment for Endometrial cancer and Recurrence (SISTER) Study. *Res Involv Engagem*. 2025 Aug 8;11(1):95. doi: 10.1186/s40900-025-00760-w. PMID: 40781345; PMCID: PMC12333272
242. Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, **Swisher EM**, Kandalaf LA, Mastroyannis SA, Montone KT, Powell DJ Jr, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. *Cancer Cell*. 2025 Aug 11;43(8):1568-1586.e10. doi: 10.1016/j.ccell.2025.07.005. Epub 2025 Jul 31. PMID: 40749672
243. McGehee CD, Meng XW, Wu X, Correia C, Venkatachalam A, Flatten KS, Peterson KL, Patel AG, Rossman OK, Wong C, Hurley RM, Wagner JM, Schneider PA, Dai H, Poirier GG, Hendrickson AEW, **Swisher EM**, Pandey A, Li H, Kaufmann SH. Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. *Nucleic Acids Res*. 2025 Oct 14;53(19):gkaf990. doi: 10.1093/nar/gkaf990. PMID: 41099700 PMCID: PMC12526053
244. Mariner BL, Sands B, Yun S, Jones T, **Swisher EM**, McCormick MA, Mendenhall AR. Diverse Patterns of Allele-Specific Expression in Healthy Human Tissues. *bioRxiv [Preprint]*. 2025 Oct 14:2025.10.14.682127. doi: 10.1101/2025.10.14.682127. PMID: 41279971; PMCID: PMC12632858
245. Rios-Doria E, Reichel JB, Radke MR, Manhardt E, Rubin-Saika M, Lockwood C, **Swisher EM**, Banda K. Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series *Curr Oncol*. 2025 Oct 21;32(10):585. doi: 10.3390/curroncol32100585. PMID: 41149505, PMCID: PMC12563156
246. Wilke RN, Pennington KP, Gootzen TA, Steenbeek MP, de Hullu JA, Long KC, Blank SV, **Swisher EM**, Lu KH, Norquist B. *Am J Obstet Gynecol*. Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precaution. 2025 Nov 1:S0002-9378(25)00820-8. doi: 10.1016/j.ajog.2025.10.044. Online ahead of print. PMID: 41183726
247. Rios-Doria E, Reichel JB, Radke MR, Manhardt E, Rubin-Saika M, Lockwood C, **Swisher EM**, Banda K. Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series. *Curr Oncol*. 2025 Oct 21;32(10):585. doi: 10.3390/curroncol32100585. PMID: 41149505; PMCID: PMC12563156
248. Devine B, Aalbers SE, Chan H, Jiang S, Dusic EJ, Knerr S, Harris HM, Wang C, Norquist BM, Riemann LA, Brant JM, Shirts BH, **Swisher EM**. Cost-effectiveness of primary care-based risk assessment and

hereditary cancer genetic testing. *BMC Prim Care*. 2025 Dec 22;27(1):33. doi: 10.1186/s12875-025-03137-w. PMID: 41423596; PMCID: PMC12859946

249. Beers FA, Theorin TN, Dusic EJ, Harris HM, Knerr S, Cameron D, Trinidad SB, Norquist BM, Raff ML, Brant JM, Bowen DJ, **Swisher EM**, Wang C. Patient-reported actions following receipt of pathogenic hereditary cancer genetic test results: results from a population-based screening study in primary care. *BMC Prim Care*. 2026 Feb 18. doi: 10.1186/s12875-026-03178-9. Epub ahead of print. PMID: 41709156
250. Banda K, Davies HR, Kumar Y, Memari y, Degasperis A, Radke M, Rodriguez I, Gooley TA, Katz R, Menghi D, Harding T, Lin K, Liu ET, Nik-Zainal S, **Swisher EM**. HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications. *Clinical Cancer Research* 2026 *in press*.

### **CONSORTIA PUBLICATIONS**

1. Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. *Nature*. 2017 Mar 16;543(7645):378-384. PMID: 28112728 PMCID: PMC5354998
2. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L; MC3 Working Group; Cancer Genome Atlas Research Network. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Syst*. 2018 Mar 28;6(3):271-281.e7. PMID:29596782
3. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; Cancer Genome Atlas Network. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Syst*. 2018 Mar 28;6(3):282-300.e2. PMID:29596783 PMCID:PMC5892207
4. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhi R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WT, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep*. 2018 Apr 3;23(1):313-326.e5. PMID:29617669
5. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; Cancer Genome Atlas Research Network, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Rep*. 2018 Apr 3;23(1):297-312.e12. PMID:29617668 PMCID:PMC5906131
6. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG; Cancer Genome Atlas Research Network, Buonamici S, Yu L. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Rep*. 2018 Apr 3;23(1):282-296.e4. PMID:29617667 PMCID:PMC5933844
7. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ; Cancer Genome Atlas Research Network, Vincent B, Eyrales E, Chen K,

- Shmulevich I, Chen F, Ding L. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. *Cell Rep.* 2018 Apr 3;23(1):270-281.e3. PMID:29617666
8. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN; Cancer Genome Atlas Research Network, Bathe OF, Liang H. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Rep.* 2018 Apr 3;23(1):255-269.e4. PMID:29617665 PMCID:PMC5916795
  9. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I; Cancer Genome Atlas Research Network, Monnat RJ Jr., Xiao Y, Wang C. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Rep.* 2018 Apr 3;23(1):239-254.e6. PMID:29617664 PMCID:PMC5961503
  10. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; Cancer Genome Atlas Research Network, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. *Cell Rep.* 2018 Apr 3;23(1):227-238.e3. PMID:29617662 PMCID:PMC5916809
  11. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H; Cancer Genome Atlas Research Network, Piwnica-Worms H, Ma L, Liang H. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Rep.* 2018 Apr 3;23(1):213-226.e3. PMID:29617661 PMCID:PMC5916807
  12. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Rep.* 2018 Apr 3;23(1):194-212.e6. PMID:29617660
  13. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J; Cancer Genome Atlas Research Network, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Rep.* 2018 Apr 3;23(1):181-193.e7. PMID:29617659 PMCID:PMC5943714
  14. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; Cancer Genome Atlas Research Network, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Rep.* 2018 Apr 3;23(1):172-180.e3. PMID:29617658 PMCID:PMC5918694
  15. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; Cancer Genome Atlas Research Network, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell.* 2018 Apr 5;173(2):400-416.e11. cell.2018.02.052. PMID:29625055

16. Chen H, Li C, Peng X, Zhou Z, Weinstein JN; Cancer Genome Atlas Research Network, Liang H. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*. 2018 Apr 5;173(2):386-399.e12. Cell.2018.03.027. PMID:29625054 PMCID:PMC5890960
17. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavitai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*. 2018 Apr 5;173(2):371-385.e18. cell.2018.02.060. PMID:29625053
18. Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Huchtagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ; Cancer Genome Atlas Research Network, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*. 2018 Apr 5;173(2):355-370.e14. PMID:29625052 PMCID:PMC5949147
19. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ; Cancer Genome Atlas Research Network, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell*. 2018 Apr 5;173(2):338-354.e15. PMID:29625051 PMCID:PMC5902191
20. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandath C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*. 2018 Apr 5;173(2):321-337.e10. PMID:29625050
21. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavitai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G; Cancer Genome Atlas Research Network. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. *Cell*. 2018 Apr 5;173(2):305-320.e10. PMID:29625049 PMCID:PMC5916814
22. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*. 2018 Apr 5;173(2):291-304.e6. PMID:29625048 PMCID: PMC5957518

23. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Peadarallu CS, Lazar AJ, Sakai R; Cancer Genome Atlas Research Network, Thorsson V, Bass AJ, Laird PW. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*. 2018 Apr 9;33(4):721-735.e8. PMID:29622466 PMCID:PMC5966039
24. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; Cancer Genome Atlas Research Network, Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*. 2018 Apr 9;33(4):706-720.e9. PMID:29622465
25. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*. 2018 Apr 9;33(4):690-705.e9. PMID:29622464 PMCID:PMC5959730
26. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; Cancer Genome Atlas Research Network, Cherniack AD, Beroukhi R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*. 2018 Apr 9;33(4):676-689.e3. PMID:29622463
27. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadarallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. *Immunity*. 2018 Apr 17;48(4):812-830.e14. PMID:29628290 PMCID:PMC5982584
28. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhi R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep*. 2018 Jun 19;23(12):3698. PMID:29925010
29. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; Cancer Genome Atlas Research Network, Ratsch G. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell*. 2018 Aug 13;34(2):211-224.e6. Epub 2018 Aug 2. PMID:30078747
30. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS,

Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*. 2018 Aug 9;174(4):1034-1035. No abstract available. PMID:30096302

31. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikummar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- $\beta$  Superfamily. *Cell Syst*. 2018 Oct 24;7(4):422-437.e7. Epub 2018 Sep 26. PMID:30268436. PMCID: PMC6370347
32. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Rep*. 2018 Oct 30;25(5):1304-1317.e5. PMID:30380420 PMCID: PMC6326181
33. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. *Immunity*. 2019 Aug 20;51(2):411-412. No abstract available. PMID:31433971
34. Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, Ewald AJ, Fu H, Jagu S, Kemp CJ, Kim W, Kuo CJ, McManus M, B Mills G, Mo X, Sahni N, Schreiber SL, Talamas JA, Tamayo P, Tyner JW, Wagner BK, Weiss WA, Gerhard DS; Cancer Target Discovery and Development Network. An expanded universe of cancer targets. *Cell*. 2021 Mar 4;184(5):1142-1155. PMID: 33667368; PMCID: PMC8066437.

#### **BOOK CHAPTERS**

1. **Swisher EM**, Mutch D. Gestational Trophoblastic Disease. In *Atlas Of Gynecology, Vol IV: Contemporary Clinical Management of Gynecological Malignancies*, BE Greer (ed), Current Medicine, Philadelphia, PA 1999.
2. **Swisher EM**. Hereditary Cancers in Obstetrics and Gynecology. in *In Gynecologic Surgery and Updates. Clinical Obstetrics and Gynecology Volume 44:3*. Gabbe SG, Scott JRt, Mutch DM. Lippincott Williams & Wilkins, September 2001
3. Swensen RE, Goff BA, Koh W-J, Petersdorf SH, Douglas JG, **Swisher EM**, Greer BE. Cancer in the Pregnant Patient. In *Principles And Practice Of Gynecologic Oncology, Fourth Edition, Chapter 36:1279-1312*, Hoskins WJ, Perez CA, Young R, Barakat R, Markman M, Randall M (eds), Lippincott Williams & Wilkins, Philadelphia, PA 2004
4. **Swisher EM** and Calhoun KE. Management of Women with Inherited BRCA1 and BRCA2 Mutations. In *The Role of Genetics in Breast and Reproductive Cancers*, Welch P (ed), Springer Science + Business Media and Humana Press, New York, NY, 2009

## **OTHER PUBLICATIONS**

1. **Swisher EM.** Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. *Curr Womens Health Rep.* 2003 Feb;3(1):27-32. PMID: 12521547
2. **Swisher EM.** Comment on "Malignant mixed Mullerian tumor of the ovary: an argument for BRCA3 or a coincidental cluster of unconnected cancer". *Gynecol Oncol.* 2004 Dec;95(3):773-4. PMID:15582005
3. **Swisher EM, Garcia R.** Reply to letter on Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer: *Am J Obstet Gynecol.* 2006.
5. **Swisher EM, King MC.** Defining women at high risk of ovarian cancer. *Cancer Res.* 2007 March;67(6):2902. PMID:17363619
6. Leiserowitz GS, **Swisher EM.** SGO's 40th Annual Meeting on Women's Cancer, *Gynecol Oncol.* 2009 April;113:1,12-13.
7. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CC, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, **Swisher E**, Weitzel JN; National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. *J Natl Compr Canc Netw.* 2010 May;8(5):562-94. PMID:20495085
8. Levine DA, **Swisher EM.** Gynecologic cancer genomics in the modern era. *Gynecol Oncol* 2013 Mar;128(3):407-8. PMID: 23399003
9. **Swisher EM.** Risk-Reducing Oophorectomy in Women with BRCA1 and BRCA2 Mutations: An Opportunity to Personalize Recommendations for Cancer Prevention. *J Clin Oncol Podcast.* 2014 Mar 31
10. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, **Swisher E.** Response. *J Natl Cancer Inst.* 2014 June 4;106(6):dju131. PMID:24899680
11. Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, **Swisher E**, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R. Genetic/Familial high-risk assessment: breast and ovarian, version 1.2014. *J Natl Compr Canc Netw.* 2014 Sep;12(9):1326-38. PMID:25190698
12. **Swisher EM,** Norquist BM, Pennington KP, Rendi MH, Garcia RL. DNA repair mutations and outcomes in ovarian cancer response. *Clin Cancer Res.* 2015 Feb 1;21(3):659. PMID:25646182
13. **Swisher EM.** Usefulness of Multigene Testing: Catching the Train That's Left the Station. *JAMA Oncol.* 2015 Oct 1;1(7):951-2. PMID: 26270409
14. Norquist BM, **Swisher EM.** More genes, more problems? Benefits and risks of multiplex genetic testing. *Gynecol Oncol.* 2015 Nov;139(2):209-10. PMID: 26521152
15. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, **Swisher E**, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. *J Natl Compr Canc Netw.* 2016 Feb;14(2):153-62. PMID: 26850485

16. **Swisher EM**, Garcia, RL, Kilgore, M, Norquist BM. Culprit or Bystander? The Role of the Fallopian Tube in "Ovarian" High-Grade Serous Carcinoma. *Cancer Discov.* December 1 2016 (6)(12) 1309-1311; PMID:27920138
17. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, **Swisher E**, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. *J Natl Compr Canc Netw.* 2017 Jan;15(1):9-20. PMID: 28040716
18. **Swisher EM**. Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib: updated data from the ARIEL2 trial presented at SGO 2017. *Doctors Lounge (invited commentary).*

### **REGIONAL INVITED LECTURES AND COMMUNITY EDUCATION**

Lecture to High Risk Support Group, Team Survivors Northwest  
Seattle, WA, September 12, 2000

BRCA1 Promoter Methylation and Protein Expression in Epithelial Ovarian Cancer  
Women's Reproductive Health Research Symposium, Seattle, WA, June 1, 2001

BRCA1 Promoter Methylation and Protein Expression in Epithelial Ovarian Cancer  
Annual Meeting of the Felix Rutledge Society, Seattle, WA, June 14, 2001

Use of Mitochondrial Variants To Identify Tumor DNA In The Plasma of Patients with Ovarian Cancer  
Women's Reproductive Health Research Symposium, Seattle, WA, May 24, 2002

Circulating Plasma DNA as a Potential Diagnostic Tool in Ovarian Cancer  
Gynecologic Cancer Research Program. Fred Hutchinson Cancer Research Center, Seattle, WA, January 8, 2003

A Transgenic Mouse Model Ties Together Longevity and Metabolism.  
Medical Genetics Journal Club, University of Washington, Seattle, WA, February 19, 2003

Ovarian Cancer Prevention  
High Risk Support Group Meeting, Team Survivors Northwest. Seattle, WA, September 16, 2003

Hereditary Cancer Predisposition: Recognition and Management of At-risk Individuals  
Grand Rounds, Roosevelt Women's Clinic, University of Washington, September 8, 2003.

Molecular Approaches to Ovarian Cancer Detection: Use of Genetic Alterations to Identify Tumor DNA in Plasma and Peritoneal Fluid  
Markey Medical Genetics Seminar, University of Washington, Seattle, WA, February 6, 2004

Molecular Diagnostics in Ovarian Cancer: New Predictors of Disease and Outcome  
Gynecologic Cancer Research Program. Fred Hutchinson Cancer Research Center, Seattle, WA, April 7, 2004

Evaluation and Management of Hereditary Cancer Risk.  
Obstetrics Grand Rounds, Oregon Health Science University, Portland, OR, May 14, 2004

Molecular Diagnostics in Ovarian Cancer: New Predictors of Disease and Outcome  
Obstetrics and Gynecology Departmental Research Conference, University of Washington, Seattle, WA, June 2, 2004

Ethics and Genetics.

Women's Lunch Series, University of Washington School of Medicine, Seattle, WA, February 10, 2005

Molecular Characterization of Epithelial Ovarian Cancer.

Ovarian Cancer Working Group Seminar, Genentech Inc., South San Francisco, CA, February 18, 2005

Gastric Cancer Originating from Bone Marrow-Derived Cells.

Medical Genetics Journal Club, University of Washington, Seattle, WA March 2, 2005

Ovarian Cancer Risk and Prevention: Information Breast Cancer Survivors Need to Know

Avon Breast Cancer Seminar, Seattle Cancer Care Alliance, Seattle, WA, April 8, 2005

Genetics of Breast and Ovarian Cancer: the Role of Genetic Testing to Identify Cancer Risk

Women's Wellness Clinic, Seattle Cancer Care Alliance, Seattle, WA, June 12, 2005

Updates on the Breast and Ovarian Cancer Prevention Program.

Women's Health Care Center Grand Rounds, University of Washington, Seattle, WA, November 14, 2005

Gene Expression in High-risk Ovarian Epithelium

Gynecologic Cancer Research Program. Cancer Consortium, Seattle, WA, January 4, 2006

Gene Expression in High-risk Ovarian Epithelium.

Obstetrics and Gynecology Departmental Research Conference, University of Washington School of Medicine, Seattle, WA, January 4, 2006

Cancer Prevention Programs: Breast and Ovarian (BOCPP), Gastrointestinal (GICPP). Women's Wellness Program

University of Washington Development Seminar, Seattle, WA, March 13, 2006

Update on Risk-reducing Salpingo-oophorectomy

High Risk Support Group, Team Survivors Northwest, Seattle, WA, April 18, 2006

Ovarian Cancer Screening and Prophylactic Surgery

Hereditary Breast and Ovarian Cancer Symposium, Seattle Cancer Care Alliance, Seattle, WA, March 4, 2006

Hereditary Breast and Ovarian Cancer- Who is at Risk and What to do About It?

Temple Beth Am, Seattle, WA, October 12, 2008.

Beyond BRCA1 and BRCA2: New Frontiers and Utility of Testing Other Breast Cancer Genes

Challenges in Clinical Cancer Genetics, University of Washington, Seattle, WA, September 27, 2010

Massively Parallel Sequencing to Identify Hereditary Ovarian Carcinoma

Gynecologic Cancer Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA, March 23, 2011

Ovarian Cancer Genetics

Medical Genetics Case Conference, University of Washington, Seattle, WA, October 19, 2011

Hereditary Ovarian Cancer Identified by Massively Parallel Sequencing

Solid Tumor Affinity Group, Fred Hutchinson Cancer Research Center, Seattle, WA, December 13, 2011

Ovarian Carcinoma – Risk Assessment & Prevention

Seattle Gynecologic Society Fall Assembly, Seattle, WA, September 28, 2012

Gynecologic Cancers in Lynch Syndrome – Risk, Screening and Prevention  
Care of the Family with Lynch Syndrome, University of Washington, Seattle, WA, March 22, 2013

Addressing the High Mortality of Ovarian Cancer  
University Sunrise Rotary Club, Seattle, WA, February 25, 2016

DNA Repair Deficiency and Therapeutic Opportunities in Ovarian Cancer  
Program in Prostate Cancer Research (PPCR) SPORE Seminar Series, Fred Hutchinson Cancer Research Center, Seattle, WA, February 25, 2016

Should all Women be Tested for BRCA Genes?  
General Internal Medicine Retreat Presentation, University of Washington, Seattle, WA, May 18, 2016

BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma  
11th Biennial Ovarian Cancer Research Symposium, American Association for Cancer Research and the Rivkin Center for Ovarian Cancer, University of Washington, Seattle, WA, September 13, 2016

Identifying Hereditary Ovarian Cancer Risk: An Opportunity to Save Lives  
Obstetrics and Gynecology Grand Rounds, University of Washington, Seattle, WA, September 21, 2016

Understanding Therapeutic Sensitivity and Resistance to PARP inhibitors  
Helen Golde Lecture and CCSG Breast & Ovary Cancer Research Program Retreat, Fred Hutchinson Cancer Research Center, Seattle, WA, May 23, 2018

Hereditary Cancer Risk- How a Spit Test Could Save Your Life. Featured Speaker for UW Medicine DocTalks, University of Washington School of Medicine Reunion, University of Washington, Seattle, WA, June 2, 2018

Genetic Testing Online: The Good, The Bad, and The Ugly. Featured Speaker at the Sunset Club, Seattle, WA June 27, 2018

Therapy Related Myeloid Neoplasia in Ovarian Cancer Patients  
Leukemia Meeting, Seattle Cancer Care Alliance, Seattle, WA, January 28, 2022

Understanding Ovarian Cancer: A Journey to Personalized Prevention and Treatment  
Science in Medicine Lecture, University of Washington, Seattle, WA, February 9, 2022

New Advances in Cervical Cancer Research and Treatment, Breast and Cervical Health Prevention Conference, May 20, 2024 Seattle, WA

### **NATIONAL AND INTERNATIONAL INVITATIONAL LECTURES**

Clinical problems in genetic testing: variants of unknown significance (Session Chair)  
ASCO Annual Meeting, Atlanta, GA, June 4 and June 6, 2006

Recognition and prevention of hereditary ovarian cancer  
Norman J. Probstin Lecture, Washington University, St Louis, MO, March 28, 2007

Ovarian cancer risk management.  
4<sup>th</sup> Annual Joining FORCES against Hereditary Cancer, Buena Vista, FL, May 16, 2009

Hereditary breast and gynecological cancer  
All-Alaskan Medical Conference, Anchorage, AK, October 9, 2009

Clinical implication of the acquisition of BRCA1/2 function in BRCA1/2-deficient ovarian carcinoma.  
SPORE Annual Meeting, Fox Chase Cancer Center, Philadelphia, PA, September 26, 2009

New insights into the prevention and treatment of hereditary ovarian carcinoma.  
Obstetrics and Gynecology Grand Rounds Visiting Professor, University of Wisconsin, Madison, WI,  
September 9, 2010

Genetics of ovarian cancer.  
Ovarian Cancer Survivors' Course, Cedars Sinai Medical Center, Los Angeles, CA, October 30, 2010

Somatic and germline mutations in dna repair genes in ovarian carcinoma  
Visiting professor seminar, Ovarian SPORE, The Mayo Clinic, Rochester, MN, May 20, 2011

Massively parallel sequencing yields new genes for inherited ovarian carcinoma.  
Scientific Session, Gynecologic Oncology Group Winter Meeting, San Diego, CA, January 26, 2012

Risk assessment and prevention for ovarian carcinoma.  
Gary Johnson, MD, Memorial Lectureship, Salt Lake City, UT, September 6, 2012

The FA-BRCA pathway in ovarian carcinomas.  
Cedars-Sinai Women's Cancer Program Lecture Series, Los Angeles, CA, December 2, 2012

Genetic susceptibility to ovarian cancer: beyond the usual suspects.  
Walter and Eliza Hall Institute of Medical Research, Women in Science Lecture, Melbourne, Australia,  
February 13, 2013

Somatic and germline mutations in homologous recombination genes predict outcomes in ovarian, fallopian  
tube, and peritoneal carcinomas.  
Lorne Cancer Conference, Lorne, Australia, February 16, 2013

The use of cancer gene panels in genetic assessment.  
Educational Symposium  
Society of Gynecologic Oncology Annual Meeting, Los Angeles, CA, March 9, 2013

DNA repair genes and ovarian cancer risk.  
Victoria Comprehensive Cancer Center Ovarian Cancer Symposium, Melbourne, Australia (by live video link),  
August 6, 2013

Identifying patients at high-risk of ovarian carcinoma.  
4<sup>th</sup> Annual Genetics Conference: Hereditary Cancers: Advanced Topics for Community Oncology Providers,  
New Orleans, LA, September 13, 2014

DNA repair deficiency: identifying therapeutic opportunities in ovarian cancer.  
Joint Symposium of Dana-Farber/Harvard Cancer Center Programs in Breast and Gynecologic Cancer,  
Boston, MA, March 6, 2015

Genetic evaluation for gynecologic cancers.  
Mayo Fellows, Rochester, MN, March 19, 2015

PARP inhibitor therapy: therapeutic development and potential in ovarian cancer.  
Society of Gynecologic Oncology Annual Meeting, Chicago, IL, March 29, 2015

Universal screening for BRCA1/2 mutations: good idea or bad idea?  
2015 ASCO Annual Meeting, Chicago, IL, June 2, 2015

Precision/molecular testing in clinical practice debate.  
Society of Gynecologic Oncology, Littleton, CO, July 17, 2015

Assessing hereditary ovarian cancer risk in the modern genomics era.  
Camel Lectureship Grand Rounds, Washington University School of Medicine, St. Louis, MO, September 9, 2015

Assessing hereditary ovarian cancer risk in the modern genomics era.  
MD Anderson Grand Rounds, Houston, TX, December 16, 2015

Ovarian cancer dream team update.  
Stand Up To Cancer Scientific Summit, Santa Monica, CA, January 27, 2016

DNA repair therapies for ovarian cancer.  
National Ovarian Cancer Coalition (NOCC) National Conference, Baltimore, MD, February 28, 2016

Evaluation of combination strategies and emerging role of PARP inhibitors in earlier-stage oc and other gynecologic cancers.  
Satellite Symposia by Research To Practice (RTP): Addressing Current Questions and Controversies: PARP Inhibition in the Management of Ovarian Cancer and Other Gynecologic Malignancies at SGO Annual Meeting, San Diego, CA, March 19, 2016

Beyond BRCA: other genetic markers for high risk women and prophylactic surgery for high risk women.  
Society of Gynecologic Oncology APP Educational lecture, San Diego, CA, March 20, 2016

Therapeutic application of PARP inhibitors- expanding their clinical utility  
New Strategies to Maximally Target DNA Repair in Cancer (Major Symposium Chair). AACR Annual Meeting, New Orleans, LA, April 18, 2016

DNA repair deficiency and therapeutic opportunities in ovarian cancer.  
UAB Comprehensive Cancer Center Research Seminar Series lecture, Birmingham, AL, May 12, 2016

Identifying hereditary ovarian cancer risk – an opportunity to save lives.  
UAB 1st Annual Brittany Waldrep Endowed Lectureship in Gynecologic Oncology, Birmingham, AL, May 13, 2016

Your genome, somatic alterations, and implications for prevention.  
Expanding the Clinically Actionable Cancer Genome (Session Chair), ASCO Annual Meeting, Chicago, IL, June 4, 2016

Identifying hereditary ovarian cancer risk: an opportunity to save lives.  
Medical College of Wisconsin Cron Memorial Lecture, Milwaukee, WI, June 22, 2016

Saving lives with ovarian cancer prevention – an update from the SU2C ovarian cancer dream team.  
Ovarian Cancer Research Fund Alliance (OCRFA) Webinar, September 22, 2016

Predictive biomarkers for PARP inhibitor therapy.  
Radiation Oncology Retreat celebrating the Scientific Accomplishments and Birthday of Alan D'Andrea, M.D. Symposium: Genome Stability and DNA Repair in Health and Disease. Harvard Medical School Boston, MA, October 7, 2016

An update from the SU2C ovarian cancer dream team.  
Awards Night, Minnesota Ovarian Cancer Alliance. University of Minnesota Cancer and Cardiovascular Research Building, Minneapolis, MN, November 9, 2016

DNA Repair and Ovarian Cancer: opportunities for therapy and prevention.  
GynOnc TWG Presents Fall Research Symposium, University of Minnesota, Minneapolis, MN, November 10, 2016

Ovarian cancer susceptibility-reducing mortality through improved risk recognition and prevention.  
GYN Seminar Series, Mayo Clinic, Rochester, MN, November 10, 2016

DNA repair and therapy of ovarian cancer.  
MPET VFM Seminar Series, Mayo Clinic, Rochester, MN, November 11, 2016

Ovarian cancer dream team update.  
Stand Up To Cancer Scientific Summit, Santa Monica, CA, January 24, 2017

DNA therapies for ovarian cancer and predictors of response and resistance.  
2nd Exploring DNA Repair Pathways as Targets for Cancer Therapy Conference, Cancun Mexico, February 28, 2017

Predictors of response and resistance to PARP Inhibitors  
Keynote Speaker, Karolinska Institutet PARP 2017, Budapest May 19, 2017

Biomarkers of DNA Repair Deficiency  
Leveraging Genomic Instability to Treat Prostate Cancer Session, 2017 Coffey-Holden Prostate Cancer Meeting, Carlsbad, CA, June 15, 2017

Ovarian cancer dream team update.  
Stand Up To Cancer Scientific Summit, Santa Monica, CA, January 30, 2018

DNA repair therapies in ovarian cancer.  
Featured Lecturer, President's Research Seminar Series (PRSS)  
Memorial Sloan Kettering Cancer Center, New York, NY, February 14, 2018

Predicting PARP Inhibitor Resistance  
Stand Up To Cancer Open Scientific Session: Bridging the Gap Between the Bench and Bedside  
American Association for Cancer Research Annual Meeting, Chicago, IL, April 16, 2018

Clinical management of ovarian carcinoma.  
American Association for Cancer Research 12th Biennial Ovarian Cancer Research  
Seattle, WA September 13, 2018

What is the current status and recommendations of germline and somatic testing in women with ovarian, fallopian tube and peritoneal cancers?  
XXII FIGO 2018 The FIGO World Congress of Gynecology and Obstetrics, Riocentro Convention Center, Rio de Janeiro, Brazil, October 15, 2018

Presenter, Simulated Molecular Tumor Board Panel Discussion  
AMP 2018 Annual Meeting & Expo, San Antonio, TX, November 1, 2018

Predictor of response to parp inhibitors.  
Plenary Session: Tumoral Genomic Diversity  
AMP 2018 Annual Meeting & Expo, San Antonio, TX, November 2, 2018

Knowing your genes: what is online genetic testing & what can it do for you.  
Alaska Foundation for Let Every Woman Know, Women's Cancer Survivor Course, Anchorage, AK, February 2, 2019

The evolution of clinical management of ovarian carcinoma.  
Let Every Woman Know, Alaska Foundation for Women's Cancer Survivor Course, Anchorage, AK, February 2, 2019

Gynecologic cancer genetic risk assessment and prevention.  
Alaska Gynecologic Cancer CME, Anchorage, AK, February 2, 2019

Clinical management of ovarian carcinoma.  
Advances and Future of High-Grade Serous Ovarian Cancer Symposium, May 8, 2019 Helsinki, Finland

Genetic assessment and treatment of ovarian carcinoma.  
Ob/Gyn Grand Rounds, University of Helsinki, May 10, 2019 Helsinki Finland

Opponent for the PhD Dissertation of Ulla-Maija Haltia, University of Helsinki, May 10, 2019 Helsinki Finland

What's new in Ovarian Cancer Research  
Ovarian Cancer Research Alliance National Conference Mello Abrams Lecture, July 13, 2019 Seattle, WA

Response and Resistance to PARP Inhibitors in Ovarian Cancer Therapy  
MRC Cancer Center Lecture, University of Cambridge, September 17, 2019, Cambridge, UK,

PARP Inhibitors in the Maintenance Setting for Ovarian Cancer  
Cancer Target Discovery and Development Network Annual Virtual Meeting, National Cancer Institute, National Institute of Health, U.S. Department of Health and Human Services, June 30, 2020

Optimizing risk assessment and prevention of hereditary ovarian cancer.  
Dana-Farber Cancer Institute, Division of Cancer Genetics and Prevention, October 21, 2020 Boston, MA (virtual)

Updates on genetics, prevention and therapy of ovarian cancer.  
OB/GYN Byford Heskett Professorship, Feinberg School of Medicine at Northwestern University, November 6, 2020 Chicago, IL (virtual)

Response and resistance to PARP inhibitors in ovarian cancer.  
The Institute of Cancer Research, Breast Cancer Program Seminar, London, England (virtual)

Lessons learned: prevention and management of drug toxicities used in gynecologic cancer.  
SGO Annual Meeting on Women's Cancer, March 19, 2021 Chicago, IL (virtual)

Final results from MAGENTA, a 4-arm randomized trial evaluating genetic counseling in remote genetic risk assessment for women with increased risk of breast and ovarian cancer.  
SU2C Cancer Interception Symposium, August 3, 2021 (webconference)

Top advances in ovarian cancer therapy.  
OVARCOME: OVARCOMING CANCER Annual Conference, September 17, 2021 (webconference)

Mayo Clinic Gyn Cancer Seminar Series: Biomarkers of AML/MDS Development in Women Treated with PARP. February 10, 2022 Rochester, MN (virtual)

Improving therapy for advanced ovarian cancer: a surgeon's journey towards personalized medicine. President's Distinguished Lecturer, 69th Annual Meeting of the Society for Reproductive Investigation (SRI) March 18, 2022 Denver, CO

PARP inhibitors and personalized treatments of ovarian cancer. University of Chicago Arthur Herbst Endowed Lecture, June 3, 2022, Chicago, IL

Addressing Challenges in Ovarian Cancer Management (Session Chair), American Society of Clinical Oncology (ASCO) Annual Meeting, June 5, 2022 Chicago, IL

Making sense of front-line maintenance options for patients with homologous repair proficient disease. American Society of Clinical Oncology (ASCO) Annual Meeting, June 5, 2022 Chicago, IL

Hereditary ovarian cancer: advances in risk assessment, prevention and treatment. Te Linde Endowed Lecture, the Department of Gynecology and Obstetrics at Johns Hopkins Johns Hopkins University School of Medicine, November 10, 2022 Baltimore, MD

PARP inhibitors in ovarian cancer: maximizing risk/benefit Center for BRCA & Related Genes Inaugural Scientific Symposium, Dana-Farber Cancer Institute, November 16, 2022 Boston, MA (virtual)

Maximizing benefit/risk of PARP inhibitors in ovarian cancer therapy Washington University, St Louis Genome Seminar, February, 3, 2023, St. Louis, MO (virtual)

Two decades of PARP inhibitors: lessons learned for precision treatment of ovarian cancer Northwest Gynecologic Cancer Symposium, September 8<sup>th</sup>, 2023, Seattle, WA

Optimizing Risk/Benefit of PARP Inhibitors for Precision Therapy of Ovarian Cancer University of New Mexico Cancer Center Director's Seminar, October 14, 2024, Albuquerque, NM

Understanding ovarian cancer: a journey to personalized prevention and treatment. Keynote speaker, University North Carolina Department of Ob/Gyn Resident Research Day, May 14, 2025, Raleigh, NC

Clonal hematopoiesis and risk of therapy-related myeloid neoplasms in tubo-ovarian cancer survivors. Invited speaker, AACR Ovarian Cancer Meeting, September 21, 2025, Denver, CO

Personalizing the risk and benefit of PARP inhibitor therapy. Fred & Pamela Buffett Cancer Center Grand Rounds, November 12, 2025, Omaha, NE

Eradicating hereditary ovarian cancer: personalizing risk assessment and prevention. New York Obstetrical Society, December 2, 2025, New York, NY

Maximizing Risk/Benefit of PARP Inhibitors in Ovarian Cancer Therapy. Sidney Kimmel Cancer Center, Director's Visiting Professor Series Talk, February 26<sup>th</sup>, 2026, Baltimore, MD

Eliminating hereditary ovarian cancer.

Johns Hopkin's Oncology Grand Rounds, February 27<sup>th</sup>, 2026, Baltimore, MD

Hematopoiesis dynamics and therapy-related myeloid neoplasia in solid tumor patients.

Immune Aging and Cancer Therapy Workshop, National Cancer Institute, March 24, 2026 (virtual)